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An abstract of a dissertation on the subject of the discovery of novel biomarkers 
of acute kidney injury by Joseph L Alge:  
Background: Acute kidney injury is a cause of significant morbidity and mortality 
in hospitalized patients. Prognostic biomarkers that predict at the time of 
diagnosis which patients will develop severe AKI and its complications would 
facilitate timely intervention and could lead to improved outcomes. The urinary 
proteome is a logical source of candidate biomarkers of kidney injury. 
Methods: Urine was collected from rodents and human subjects with AKI 
secondary to diverse etiologies, including cardiac surgery, ischemic/hypoxic 
injury, and nephrotoxicity. Shotgun proteomics was used to identify candidate 
biomarkers in four separate discovery phase experiments. These candidates 
were then verified in a larger cohort and case-control studies, in which they were 
measured using ELISA and a multiplex, quantitative mass spectrometry assay.  
Results: A total of 22 candidate prognostic biomarkers of AKI were identified by 
shotgun proteomic analysis of urine from rodents and humans with AKI. Of these, 
urinary angiotensinogen was the most promising. The prognostic predictive 
power of urinary angiotensinogen was verified in a cohort of post-cardiac surgery 
human subjects with AKI (n = 204), which found that it was a strong predictor of 
progression from Acute Kidney Injury Network (AKIN) stage 1 AKI to the 
composite endpoint AKIN stage 3 or death, having an area under the ROC curve 




an AUC of 0.7, 95% CI [0.57, 0.83] for the outcome. A classification tree model 
found that the combination of these biomarkers could predict the outcome with a 
positive predictive value of 80.4%. The quantitative mass spectrometry assay 
was able to successfully measure 11 of the 22 candidate biomarkers, and using 
this assay, the prognostic predictive power of urinary superoxide dismutase [Cu-
Zn], myoglobin was confirmed in a subset of the aforementioned cohort of post-
cardiac surgery AKI patients (n =156). SOD and myoglobin predicted progression 
from AKIN stage 1 to AKIN stage 3 or death with an AUC of 0.76 and 0.77, 
respectively. Urinary angiotensinogen was also included in the assay, and it had 
an AUC of 0.74 for the outcome. The performance characteristics of these novel 
biomarkers compared favorably with urinary liver-type fatty acid binding protein 
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Acute Kidney Injury: Definition and Classification 
Acute kidney injury (AKI) is a new term for an old problem.  It was recognized by 
ancient physicians as a decrease in urine output (oliguria) that was accompanied 
by the classic signs and symptoms of anorexia, nausea, and vomiting.1  Greek 
and Roman physicians recognized that it could arise in a variety of settings 
including crush injuries, serpent bites, and poisonings, and they understood that 
death was imminent if a patient’s condition progressed to prolonged anuria.1 
Therefore, the broadest definition of acute kidney injury, that is an abrupt 
reduction in renal function, has been recognized as a clinical syndrome since the 
time of the birth of medicine.  Of course, much has changed since then regarding 
how we define this disease, and we now use more objective measures of renal 
function such as serum creatinine (sCr) and blood urea nitrogen (BUN), which 
are filtered at the glomerulus and accumulate in the blood when glomerular 
filtration rate falls, although urine output is still a useful diagnostic and prognostic 
indicator.2-4   
Despite the availability of these conventional AKI biomarkers, for decades of 
modern medicine, there was not a consensus on the definition of AKI.  In fact, 
there was not even an accepted nomenclature and AKI has been known by other 
names including acute renal failure and acute renal dysfunction.  Lack of an 
accepted definition resulted in a broad array of diagnostic criteria being used in 
the literature, with the definition of AKI ranging from an increase in sCr  >25% 
from baseline, to an increase in sCr >2.0 mg/dL,, to the need for dialysis.5  This 




Dialysis Quality Initiative Group in 2004, an international consensus workgroup, 
which proposed the RIFLE classification system for acute renal failure.  The 
RIFLE acronym designates the different stages of acute renal failure according to 
this classification system.  They are: Risk of renal dysfunction, Injury to the 
kidney, Failure of kidney function, Loss of kidney function, and End-stage renal 
disease (ESRD). 2 Using RIFLE, patients are staged based upon changes in 
serum Creatinine (sCr) and urine output.  Furthermore, the staging system 
includes the use of the widely accepted MDRD equation to calculate estimated 
glomerular filtration rate (eGFR) and changes in eGFR, when a patient’s baseline 
sCr is unknown.  A summary of the RIFLE classification scheme is shown in 
Table 1-1.   
The RIFLE classification system was an important step toward improving the 
quality of AKI research and the care of patients with this disease.  Two salient 
features of this system include the use of baseline characteristics and the 
inclusion of outcomes in the classification scheme.  The former allows for 
accurate assessment of injury, including so-called “acute on chronic” kidney 
disease, when a patient has AKI superimposed on preexisting chronic kidney 
disease.  The latter is helpful with regard to defining clinical end-points that can 
be used in clinical trials.  An important limitation of this system is that it does not 







Table 1-1. RIFLE Classification System of Acute Renal Failure
2
 
Stage sCr and GFR Criteria Urine Output Criteria 
Risk 
↑ sCr of 1.5 fold (150%) or  ↓eGFR 
>25% 
UO <0.5ml/kg/h for more than  6 hr 
Injury 
↑ sCr of 2 fold (200%) or  ↓eGFR 
>50% 
UO  <0.5ml/kg/h for more than 12 hr 
Failure* 
↑ sCr of >3 fold (300%) or  ↓eGFR 
>75% or sCr >4mg/dl 
UO <0.3ml/kg/h for 24 hr or anuria for 12 hr 
Loss Persistent ARF= complete loss of kidney function >4 weeks 
ESRD Loss of kidney function >3 months 
Patients are staged by both GFR and urine output criteria, and are designated as the most 
severe stage reached by either criteria. 
*Patients can be classified as Rifle-F if absolute sCr is >4.0 mg/dL with an acute increase of 
≥0.5 mg/dL. 






urine output.  Despite this limitation, RIFLE was widely accepted by the 
nephrology community and continues to be frequently used in the literature.  
In 2007, the Acute Kidney Injury Network, an international workgroup, published 
a new definition and classification system, which made several important 
changes to the RIFLE definitions (Table 1-2).   First, this group proposed 
changing the nomenclature of acute renal failure to acute kidney injury.3  The 
latter is a more inclusive term, representing the entire spectrum of acute renal 
failure.  The newly proposed definition of AKI was  
“An abrupt (within 48 hours) reduction in kidney function currently 
defined as an absolute increase in serum creatinine of more than or 
equal to 0.3mg/dl (>26.4 µmol/L), a percentage increase in serum 
creatinine of more than or equal to 50% (1.5-fold from baseline), or a 
reduction in urine output (documented oliguria of less than 0.5ml/kg 
per hour for more than six hours).”3 
 
The AKIN classification made several other modifications to the RIFLE definition 
and staging system.  The specification of a brief time window allows for the 
clinical distinction of acute injury.  Additionally, the lowering of the minimum 
required increase in sCr to 0.3mg/dl reflects research which had demonstrated 
that even small increases in sCr are associated with a higher risk of adverse 
outcomes.6,7  Thus, the AKIN definition of AKI is intentionally a more sensitive 
diagnostic tool than the RIFLE criteria, and its increased sensitivity compared to 
RIFLE has been documented.8    Using the AKIN criteria, patients are still staged 
according to the most severe changes in serum creatinine and urine output. 
However, the AKIN criteria largely omit the outcome measures included in the 








Table 1-2 .  Acute Kidney Injury Network (AKIN) Classification System for AKI
3
 
Stage sCr Criteria Urine Output Criteria 
1 
↑ sCr of 0.3mg/dl or 1.5-2 fold (150-200%)  from 
baseline 
UO <0.5ml/kg/h for more 
than  6 hr 
2 ↑ sCr of 2-3 fold (200-300%) 
UO <0.5ml/kg/h for more 
than 12 hr 
3 
↑ sCr of >3 fold  (>300%) or sCr >4.0mg/dl with acute 
increase of >0.5mg/dl or RRT 
UO <0.3ml/kg/h for 24 hr 
or anuria for 12 hr 




therapy (RRT) are automatically considered AKIN Stage III.   In summary, the 
AKIN definition and classification system changed the terminology of acute renal 
failure to acute kidney injury, added the element of time to the diagnostic criteria, 
and lowered the diagnostic threshold of increased sCr in order to increase 
sensitivity.   
Finally, in 2012 the Kidney Disease Improving Global Outcomes (KDIGO) 
consortium issued a revised definition of AKI which unifies the RIFLE and AKIN 
classification systems.  One of the major criticisms of the AKIN criteria has been 
that the specified 48 hour time window is too short, and if applied it could result in 
a substantial number of false negatives from patients whose sCr increases at an 
atypically slow rate.  Therefore, KDIGO proposed the minimum threshold for AKI 
to be an increase in sCr ≥0.3 mg/dL over 48 hours or ≥50% from baseline over 1 
week.9  However, the KDIGO guideline was only released in 2012, and thus its 
proposed changes to the definition of AKI have not had time to be studied.   
The Etiology of Acute Kidney Injury 
AKI is one of the most common conditions seen in the hospital.  Its commonness 
is in part a reflection of its poly-etiological nature, with possible etiologies having 
classically been grouped into three categories, pre-renal, intra-renal and post-
renal.10  Pre-renal AKI refers to a loss of glomerular function that is the result of 
decreased renal perfusion, and by definition, it is reversible following correction 
of renal perfusion.10  Common causes of pre-renal AKI include hypovolemia, 
congestive heart failure, cardiogenic shock, and pharmacotherapy that adversely 




AKI can be caused by anything that obstructs urine flow, at any level of the 
urinary tract between the renal pelvis and the urethra.10  This obstruction causes 
an increased pressure in Bowman’s space, which opposes glomerular filtration, 
thereby impairing renal function.  However, in a healthy person such an 
obstruction must be bilateral to cause AKI, since one kidney can compensate for 
the loss of the other.  Nevertheless, post-renal AKI can occur, for example in 
benign prostatic hypertrophy, retroperitoneal fibrosis, or neurogenic bladder 
following spinal cord injury.10 
In contrast to the relatively straightforward mechanisms underlying pre- and post-
renal AKI, intra-renal, or intrinsic, AKI is a complex, often multifactorial disease 
process.  Intrinsic AKI is the result of damage directly to the kidney parenchyma, 
and can be subclassified based upon the site of injury (i.e. glomerular, tubular, 
interstitial, or vascular), with the tubules being most commonly affected.10  The 
most common causes of intra-renal AKI are ischemia and nephrotoxicity.10   
Because they are highly metabolically active yet exist in a hypoxic environment, 
renal tubular epithelial cells are exquisitely sensitive to hypoxic injury.13  Thus, 
anything that impairs renal perfusion can cause tubular injury.  A logical 
consequence is that ischemic-hypoxic tubular injury commonly occurs secondary 
to pre-existing pre-renal AKI.  It must also be noted that AKI is a common 
complication of sepsis, and sepsis accounts for between 20 and 50% of AKI 
cases.14,15  Sepsis drastically alters renal hemodynamics resulting in ischemic 
injury, and the accompanying inflammatory response further exacerbates renal 




exposure to exogenous toxins, such as certain pharmacological agents, including 
the aminoglycosides and cisplatin.10  However, the most common cause of 
nephrotoxic AKI is radiocontrast exposure, which accounts for approximately 
10% of AKI cases in the intensive care unit.10,15  Nephrotoxicity can also be the 
result of endogenous toxins, most commonly heme from hemoglobin, and 
myoglobin, which are released following damage to erythrocytes and skeletal 
myocytes, respectively.  Therefore, intra-renal AKI is often seen in the settings of 
malarial infection and rhabdomyolysis.17,18     
Finally, no discussion of the etiology of AKI would be complete without 
mentioning it as a post-operative complication, as surgical causes account for 
approximately one-third of AKI cases.14  AKI is particularly common after cardiac 
surgery, affecting about 20% of patients who undergo cardiac procedures.8  Of 
note, the cardiac surgery population is an ideal population in which to study AKI, 
and especially AKI biomarkers given the predictable nature of the injury and the 
ease of determining its timing and severity.  Additionally, AKI after cardiac 
surgery has a complex and multifactorial pathogenesis involving ischemia-
reperfusion injury, inflammation, and nephrotoxicity from lysed erythrocytes, 
making it likely that studies performed in this population will be generalizable to 
other etiologies of AKI.19 
The Epidemiology of Acute Kidney Injury 
AKI is one of the most common diseases observed in hospitalized patients, and 




prospective multicenter studies have been conducted to accurately assess the 
impact of community acquired acute kidney injury, retrospective observational 
studies estimate that 1.0- 9.6% of hospitalized patients are admitted with AKI, 
which accounts for approximately three-quarters of all AKI cases.21-23  
Community acquired AKI is usually pre-renal, secondary to volume depletion.21,23  
Consequently, it is associated with a lower mortality and a lesser risk of adverse 
outcomes than hospital acquired AKI.23  In contrast, the burden of hospital-
acquired AKI is well documented.  Estimates from single-center retrospective 
studies are that 4.9 – 7.2% of patients admitted without AKI will develop AKI 
during their hospital stay.24,25  Complementary of this data are the results of two 
large studies performed using administrative databases, which have reported 
that 2.1 – 3.6% of all hospital discharges are associated with ICD-9 codes related 
to AKI, although it should be noted that database studies are less accurate for 
the identification of patients with mild AKI, and likely under-report AKI 
diagnosis.26-28  Nevertheless, these studies have identified trends of increasing 
incidence and decreasing mortality over the past 25 years.26,27  Lastly, it should 
be noted that the incidence of AKI is disproportionately high in the critically ill 
population.  Large multicenter epidemiologic studies estimate that the incidence 
of severe AKI is 5.7-7.7%, with an associated mortality rate in excess of 
50%.14,29,30  However, it is important to note that studies which included patients 
with less severe AKI, for example RIFLE risk or AKIN stage 1 as inclusion 
criteria, have found a much higher incidence, ranging from 16.2%-35.8 and a 




AKI is associated with a number of adverse outcomes.  As mentioned above, AKI 
increases the risk of death, both over the short and long-term, and dialysis-
dependent AKI is an independent risk factor for in-hospital mortality.6,7,22,34,35  
Importantly, even mild AKI confers an increased risk of death.6,7  In addition to 
mortality, AKI has been associated with an increased length of hospital stay and 
greater medical costs.6  Finally, it is important to note that the risk of adverse 
outcomes, particularly mortality, increases proportionally with AKI severity, and 
patients with severe AKI bear a disproportionate burden of these outcomes.6,32,33   
It has become increasingly apparent that AKI is causally linked with chronic 
kidney disease and end-stage renal disease, two conditions of tremendous 
importance to the health care economy in the United States.36-38  The risk of 
accelerated renal function decline is greatest in those patients who already have 
chronic kidney disease at the onset of AKI (so-called acute on chronic kidney 
disease), and in these patients AKI has been called “a springboard for CKD 
progression”.38,39  However, it is noteworthy that an episode of AKI appears to 
predispose patients to ESRD, even in the absence of pre-existing CKD.38     
Conceptual Framework of Acute Kidney Injury 
The complex multifactorial, and multiphasic elements of acute kidney injury pose 
particularly vexing problems to researchers hoping to uncover the molecular 
determinants of the course of this disease.  Recognizing these complexities, 
experts have proposed two conceptual models of AKI that serve as useful 
frameworks for approaching its study.  The first model describes the progression 




model describes the interrelationships of risk factors for AKI, renal damage, and 
adverse outcomes.  Both of these models provide important background 
information pertinent to the study of AKI biomarkers and will be addressed 
separately. 
Cellular and Molecular Phases of Acute Kidney Injury 
Sutton et al. described the progression of ischemic AKI through four distinct 
phases, each one characterized by a different set of cellular and molecular 
events (Figure 1-1).40  The first phase is “initiation”, during which the proximal 
insult occurs when there is a decrease in renal blood flow leading to a decrease 
in the glomerular filtration rate (GFR).  This results in ATP depletion in the cells of 
renal tubular epithelium and consequent alterations in the actin cytoskeleton, loss 
of apical-basolateral polarity, and up-regulation of inflammatory mediators.13,40  
Cell death occurs by necrosis and apoptosis.  Persistent hypoxia leads to the 
“extension phase”, during which marked hemodynamic alterations occur due to 
damage to the microvascular endothelium and there is a severe reduction in 
perfusion to the corticomedullary junction and the outer medulla.13,40  This phase 
is also accompanied by a pronounced inflammatory response and continued 
apoptosis and necrosis of tubular epithelial cells.  During the extension phase the 
glomerular filtration rate continues to fall.  The next phase of AKI is 
“maintenance”, during which GFR stabilizes at its nadir, and serum creatinine 
plateaus.19,40  Important cellular processes occur during this phase as there is 
proliferation and migration of epithelial cells to repopulate the denuded tubular 




   
 
Figure 1-1.  Clinical phases of acute kidney injury. This figure was taken from a 
review on the molecular mechanisms and phases of ishemic AKI.(1)  Four distinct 
phase are described: initiation, extension,  maintenance, and repair/recovery.  GFR, 





in this process, although there is a small contribution from the hematopoietic 
stem cells, and a role for kidney specific stem cells cannot be ruled out. 13,41,42 
Finally, during the “recovery” phase tubular epithelial cell polarity is 
reestablished, is accompanied by the return of normal cellular and renal function, 
and the repair process is complete.13,40    
Conceptual Model of Acute Kidney Injury     
Murray et al. proposed a conceptual framework for understanding AKI which 
begins with its antecedents (Figure 1-2).43  Antecedents are conditions or events 
which put a patient at risk of developing AKI, such as existing chronic kidney 
disease, IV contrast exposure, or surgery.  Obviously there is a connection 
between these risk factors, particularly exposure to known precipitants of AKI, 
and renal damage itself.  This model points out the opportunity for scientists and 
physicians to intervene and mitigate the risk of AKI in these patients. If severe 
enough, renal damage leads to a detectable decrease in GFR, which can result 
in kidney failure and death.  Additionally, this model recognizes the abundance of 
complications of acute kidney injury that can arise, such as metabolic acidosis,  
hyperkalemia, volume overload, all of which can result in the need for acute 
dialysis, which as has already been mentioned, is an independent risk factor for 
mortality. 
These illustrative models neatly demonstrate the need for prognostic biomarkers 
that can quantify the severity of injury, predict the course of the disease, and 
assess a patient’s risk of adverse outcomes.  It is clear that surrogates of GFR 






Figure 1-2. A conceptual framework of AKI. This model proposed by Murray 
et al. identifies the progression of AKI through successive risk phases during 




because they change slowly with respect to the timing of the injury and they are 
mechanistically unrelated to the progression of the disease at a cellular and 
molecular level.  Novel biomarkers of renal injury, such as neutrophil gelatinase-
associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), interleukin-18 (IL-
18), and liver-type fatty acid binding protein (L-FABP) have been identified.  
These proteins have yielded valuable insight into the molecular underpinnings of 
AKI, and they have shown promise as early diagnostic indicators of AKI and 
predictors of prognosis.  It is to these novel AKI biomarkers that we turn our 
attention to next. 
Biomarkers of Acute Kidney Injury 
Neutrophil gelatinase-associated lipocalin 
Neutrophil gelatinase-associated lipocalin (NGAL) is a widely expressed 25 kDa 
protein of the lipocalin family.  Several excellent reviews have been published on 
its role in renal disease, and the reader is referred to these for more in-depth 
study.44-48  The known functions of NGAL primarily revolve around its ability to 
bind catechol siderophores. Toll-like receptor signaling results in significant up-
regulation of NGAL gene expression and translation, and NGAL plays an 
important role in the innate immune response where it acts as an iron-
sequestering bacteriostatic agent by binding bacterial iron-siderophore 
complexes, thereby preventing their uptake by the pathogen.49,50  NGAL is also 
implicated in iron trafficking in the kidney epithelium.  During nephrogenesis, it is 
secreted by the uteric bud and induces tubulogenesis in the metanephric mass, 




epithelium.51  It appears that this function of NGAL depends upon it being loaded 
with an iron-siderophore complex.52   
Following ischemic or nephrotoxic injury, intrarenal NGAL is dramatically up-
regulated at the transcript and protein levels.53-55   Elevated NGAL protein is 
detectable in the urine as early as 3 hours after injury, and in vivo data have 
suggested the thick ascending limb and the collecting duct as the sites of 
intrarenal NGAL production, although proximal tubule cells secrete NGAL in vitro 
in response to ATP depletion.44,54,56  Importantly, however, plasma NGAL also 
increases after AKI, as a result of increased hepatic production, and NGAL is 
filtered by the glomerulus and taken up by the proximal tubule in a megalin-
dependent manner.44,56,57  The plasma pool of NGAL protein appears to play an 
important role in modulating the severity of AKI, as it has been demonstrated that 
NGAL administered either i.v. or i.p. is delivered to the proximal tubule where it 
exerts a renoprotective effect.56,58  The effect of NGAL in the injured kidney is 
dependent on its interaction with iron-loaded siderophore, and siderophore-free 
NGAL (apo-NGAL) has no effect.56   
Both urine and plasma NGAL peak early after renal injury, within the first 6 hours, 
and consequently NGAL has been extensively investigated as an early predictor 
of AKI diagnosis (find review citation for this).  The first study to evaluate the 
predictive accuracy of NGAL for early diagnosis of AKI was performed in a 
pediatric cardiac surgery cohort (n = 71) and found that urine NGAL measured at 
2 hours post-operatively was a nearly perfect predictor of AKI (area under the 




hour post-operative time point.59  Subsequent prospective studies in children that 
have evaluated the ability of urine and plasma NGAL to predict AKI after cardiac 
surgery from an early time point have confirmed these findings, and almost 
universally have reported high predictive power, with the calculated area under  
the receiver operator curve >0.90 (Table 1-3).60-62  However, the TRIBE-AKI 
Consortium reported a much lower predictive power in their multicenter 
prospective study (n = 311).63  In this study, urine NGAL and plasma NGAL 
predicted severe AKI with an area under the receiver operator characteristic 
curve of 0.71 and 0.56, respectively, with more disappointing results for 
prediction of mild AKI (defined as RIFLE-R).63  NGAL has also been 
demonstrated to predict AKI after cardiac surgery in adults, although results have 
been less impressive in this population, where reported AUCs range from 0.61 to 
0.80, and the most definitive study to date, reported disappointing results.  In a 
prospective study of 1291 cardiac surgery patients, urine and plasma NGAL 
measured at the time of ICU arrival only had areas under the receiver operator 
characteristic curve of 0.67 and 0.70, respectively.  Similar results have been 
reported in studies of NGAL as a predictor of contrast-induced nephropathy, and 
urine NGAL is currently being used to screen post-cardiac catheterization 
patients and identify those as high risk of contrast-induced nephropathy as a 
means of guiding enrollment in a clinical trial investigating early, intensive volume 
expansion as a prophylactic for contrast-induced nephropathy.64,65  In the 
intensive care setting, both urine and plasma NGAL predict the future 




need for renal replacement therapy with high accuracy (AUC = 0.82).66,67 It 
should be noted that sepsis is a potential confounder in studies conducted on the 
critically ill, however, because septic AKI patients have higher urine and plasma 
NGAL than non-septic AKI patients, and animal models have demonstrated 
marked up-regulation of NGAL in response to septicemia.50,68   
As can be noted from Table 1-3, there is a large degree of variability in the 
results of the various studies that have been conducted to investigate the early 
predictive power of NGAL for AKI.  Much of this can be attributed to differences 
in study design such as cross-sectional versus prospective design, timing of 
NGAL measurement, correction for urine creatinine, and differences in the 
definition the primary outcome of the study.  We have tried to include as much 
information about these differences as is reasonably possible.  Nevertheless, 
such variability makes it difficult to interpret the sum of the results.  To address 
these difficulties, the NGAL Meta-Analysis Group performed a systematic review 
and meta-analysis which collated the data from 19 studies, many of which have 
been mentioned.69  They found that the predictive power of urine and plasma 
NGAL was similar, having areas under the summary ROC curve of 0.837 and 
0.775.  Importantly, it was noted that the predictive power of NGAL was highest 
for contrast-induced nephropathy, then for AKI after cardiac surgery, and then for 
AKI among the critically ill.  Additionally, NGAL had a higher predictive power in 
children (AUC = 0.93) than adults (AUC = 0.782).  These differences are thought 
to be attributed to the increased rates of comorbidities and heterogeneity in the 












Few studies have been conducted to specifically evaluate the prognostic 
predictive power of NGAL in patients with established AKI.  Among patients with 
AKI after cardiac surgery, plasma NGAL, but not urine NGAL, appears to predict 
progression to a higher AKIN stage.80  In critically-ill patients, NGAL appears to 
be a slightly better predictor of prognosis.  Hall et al. reported that urine NGAL 
had an area under the ROC curve of 0.71 for the composite outcome progression 
to a higher AKIN stage or death, and it improved the predictive power of clinical 
model for this outcome.79  Others have found that both urine and plasma NGAL 
predict AKI progression and the need for renal replacement therapy, although the 
predictive power of plasma NGAL is better.68   
Kidney Injury Molecule-1 (KIM-1) 
Kidney injury molecule-1 (KIM-1) is a 38.7 kDa transmembrane that contains 
extracellular mucin and immunoglobulin domains.81 Basal expression of KIM-1 is 
low in the normal kidney.  However, it is upregulated following ischemia 
reperfusion injury, and KIM-1 protein can be localized to proliferating epithelial 
cells of the proximal tubule 48 hours after injury.81 Expression of KIM-1 has been 
demonstrated to confer a phagocytic phenotype on cultured primary kidney cells 
via its function as a phosphatidylserine receptor, which allows it to promote the 
phagocytosis of apoptotic bodies and necrotic debris.82  Therefore, it has been 
proposed that KIM-1 could play a role in renal recovery and tubular regeneration 
following acute kidney injury. Importantly, the extracellular component of KIM-1 is 




manner.83  While the functional importance of KIM-1 shedding is unclear, it is 
ostensibly the mechanism underlying the increase in urinary KIM-1 observed 
following renal ischemic or toxic injury.84,85  The first observation that urinary KIM-
1 could be useful as an AKI biomarker was made by Han et al. who reported that 
urinary KIM-1 was significantly increased in patients with established ATN 
compared to patients with other types of renal failure, chronic kidney disease, 
and healthy controls.84 
KIM-1 has been extensively investigated as a diagnostic biomarker of AKI, and a 
lateral flow immunochromatographic assay has been developed for rapid, point 
of care detection of urinary KIM-1 (Table 1-4).86  Two early studies reported that 
KIM-1 identified established AKI in the hospitalized population with high accuracy 
(AUC = 0.93).78,87  However, these studies compared patients with severe AKI to 
control groups that included healthy subjects, which likely resulted inflated the 
predictive power of KIM-1.  Accordingly, a large study of ICU patients by Endre et 
al. found that KIM-1 measured at ICU admission had an AUC of 0.66 for 
diagnosis of AKI on entry to the ICU.88  Studies of its usefulness as an early AKI 
biomarker have produced mixed results with AUCs ranging from 0.64 to 
0.83.74,87,89,90  While most of these studies have been small, single center 
studies, the data from the TRIBE-AKI Consortium are more conclusive.  They 
recently reported that KIM-1 measured at the time of ICU arrival predicted severe 




and 0.71, respectively.90  However, the investigators noted that these results 
were not significant after adjustment for NGAL and IL-18.   
Thus, urinary KIM-1 appears to have limited utility as an early diagnostic marker 
of AKI, which is plausibly explained by the temporal relationship between renal 
injury and KIM-1 elevation.  In the TRIBE-AKI study KIM-1 did not peak until 
post-operative day 3 after cardiac surgery in adults and day 2 in children, which 
is in agreement with data from other studies, including animal models.74,85,90  This 
would seem to implicate it during the later phases of AKI, and would suggest that 
it may be a better prognostic biomarker.  However, few properly controlled, 
prospective studies have studies have evaluated KIM-1 and those that have 
been conducted have reported modest prognostic predictive power.79,91  Finally, 
the ability of KIM-1 to discriminate between ATN and other renal diseases 
suggests that it could be used to differentiate patients with transient, pre-renal 
AKI from those with more severe, true AKI.  This hypothesis is corroborated by a 
recent study by Nejat et al., which found that urinary KIM-1 was elevated in 
patients with sustained AKI compared to pre-renal AKI.92      
Interleukin-18 
Interleukin-18 (IL-18) is a 22 kDa pro-inflammatory cytokine that has been 
implicated in many different disease processes.  It is translated as a procytokine 
and must be subsequently cleaved by caspase-1 in order to be activated.  More 
specifically, caspase-1 functions as part of a multiprotein complex called the 








domain containing members of the NOD-like receptor (NLR) family of proteins, of 
which are there are 14 different types.93  The NLRs, as their name implies, 
recognize ligands which induce an inflammatory response.  Such ligands are 
numerous and quite diverse, but they can be broadly grouped into two classes: 
pathogen-associated molecular patterns (PAMPs) and damage-associated 
molecular patterns (DAMPs).  The binding of these molecules to a NLR results in 
the recruitment of scaffold proteins and proteolytic enzymes, and ultimately 
caspase-1 activation, allowing caspase-1 to proteolytically activate IL-1β and IL-
18 prior to their secretion.93 Mature IL-18 induces NF-κB signaling through the 
heterodimeric IL-18 receptor, and its proinflammatory effects are negatively 
regulated by an endogenous inhibitor, IL-18 binding protein.94-96  The 
preponderance of data suggests that IL-18 contributes to renal injury during AKI.  
The amount of mature IL-18 increases in the kidney following ischemia- 
reperfusion injury, glycerol injection, and cisplatin-induced renal injury in a 
caspase-1 dependent manner.97,98  Disruption of the IL-18 signaling axis by 1) 
knockout of NLRP3, a NOD-like receptor expressed in macrophages, 2) 
caspase-1 knockout 3) pharmacologic inhibition of caspase-1, and 4) 
pretreatment with an IL-18 neutralizing antibody have been demonstrated to 
attenuate the severity of AKI.97-100  Of note, a study by Edelstein et al. found that 
mouse proximal tubules express caspase-1 and secrete IL-18 in response to 
hypoxia, although an immune cell source of IL-18 production during AKI cannot 
be definitively ruled out.101  The precise signals that drive activation of the 




possible stimulants include reactive oxygen species, ATP (released from necrotic 
cells), and uric acid crystals (released from necrotic cells).99,102,103    
Studies which have reported on the performance of IL-18 as an AKI biomarker 
are shown in Table 1-5.  A cross-sectional study by Parikh et al. was the first 
demonstrate the potential of IL-18 as an AKI biomarker.104  This study found that 
IL-18 was an excellent discriminator between patients with established acute 
tubular necrosis (n = 14) and a diverse control group  including healthy controls 
(n = 11), prerenal azotemia (n = 8), urinary tract infection (n = 5), chronic kidney 
disease (n =12), and post-renal transplant patients (n = 22), with an impressive 
area under the receiver operator characteristic curve of 0.95.104  A more recent, 
larger study confirmed the ability of IL-18 to accurately identify established AKI.78   
Urinary IL-18 has been investigated as an early predictor of AKI diagnosis in a 
variety of settings.  In children undergoing cardiac surgery, it appears to be a 
moderate predictor of AKI at an early time point, with stronger predictive power 
for more severe AKI.105,106  In comparison, two studies in adults undergoing 
cardiac surgery have reported that IL-18 is not predictive of post-operative 
AKI.89,107  However, a large prospective study by the TRIBE-AKI Consortium has 
reported that IL-18 concentration at the time of ICU arrival (0-6 hours after the 
initiation of bypass) is a modest predictor of mild AKI and has stronger predictive 
power for severe AKI.76  Important discrepancies between these studies exist, 
which could explain the contradictory results.  These include sample size (studies 
which have reported negative results were much smaller), the use of creatinine 












sample collection.  In the more heterogenous ICU population, IL-18 predicts the 
development of AKI within 24 hours after measurement.77,108-110  However, it 
must be noted that although Washburn et al. reported that higher peak urine IL-
18 concentration was associated with higher risk of developing AKI in the 
pediatric ICU, true prediction of future AKI was not demonstrated in this study.110    
In addition to early diagnosis of AKI, IL-18 has also been investigated as a 
prognostic biomarker of AKI.  Some studies have reported that IL-18 is 
associated with an increased risk of mortality among AKI patients.108,109  
However, few studies have robustly evaluated IL-18 as a predictor of adverse 
outcomes, and often prognosis is evaluated during secondary analysis of studies 
designed to test the ability of the biomarker to predict development of AKI at an 
early time point in the disease.  In such studies, the majority of patients do not 
develop AKI and are therefore not at risk of developing adverse outcomes 
associated with AKI.  If included in an analysis of prediction of adverse 
outcomes, these patients would skew the positive and negative predictive values 
(PPV and NPV) of any biomarker cut-off selected, since PPV and NPV depend 
upon prevalence.  Therefore, estimates of the ability of IL-18 to predict adverse 
outcomes are likely unreliable.  In order to properly estimate prediction of 
adverse outcomes, patients with IL-18 below a predetermined cut-off (signifying 
diagnosis of AKI) should be excluded from the analysis.  Another approach is to 
evaluate the prognostic predictive performance of IL-18 at the time that diagnosis 
of AKI is made based on serum creatinine or urine output criteria, although such 




an ICU cohort found that IL-18 predicted worsening of AKI (defined as 
progression to a higher stage) or death with an AUC of 0.63, and a similar study 
in cardiac surgery patients by Koyner et al. reported that IL-18 had an AUC of 
0.63 for progression to a higher stage.79,80  
It is clear that IL-18 predicts severe AKI at an early time point after injury, it is a 
much less powerful predictor of mild AKI.  While it is noteworthy that even mild 
AKI is associated with adverse events, including an increased risk of mortality, it 
is well-documented that the risk of adverse outcomes associated with AKI 
increases with the severity of injury.6,7,22  While the prognostic value of IL-18 
appears to be diminished later in the course of the disease, IL-18 its ability to 
identify severe AKI at an early time point could be used to identify patients at 
high risk of adverse outcomes who could benefit from intervention. 
Liver- type Fatty Acid Binding Protein (L-FABP) 
Liver-type fatty acid binding protein (L-FABP) is expressed in the renal cortex, 
and the resultant 14 kDa protein can be localized predominantly in the proximal 
tubule.111,112 Importantly, while L-FABP can be found in the human kidney, it is 
not expressed in the murine kidney. Consequently, much of what is known about 
the factors governing the renal production of L-FABP and its effects during acute 
kidney injury has been discovered using a transgenic mouse model in which the 
genomic DNA of the human L-FABP gene, including its promoter region, was 
integrated into the mouse genome.113,114 Although studies using this transgenic 
mouse have demonstrated that urinary L-FABP concentration is predictive of the 




cisplatin,115 L-FABP has been shown to play a renoprotective role in these animal 
models of AKI.116-118 The canonical function of L-FABP is to bind long chain and 
very long chain fatty acids and promote their uptake and subsequent metabolism 
by β-oxidation.122-125  However, in the setting of renal ischemia reperfusion injury, 
Yamamoto et al. showed a significant reduction the amount of pimonidazole 
immunostaining, a marker of tissue hypoxia, in the outer medulla of the kidneys 
of mice expressing human L-FABP compared to wild type controls, suggesting 
an antioxidant role for L-FABP.  Additionally, L-FABP binds to a number of lipid 
species, and it has been postulated that it also binds to the lipid peroxidation 
products generated during ischemia reperfusion injury and promotes their 
redistributed from the cytosol to the tubular lumen when L-FABP is 
secreted.111,116  L-FABP gene expression is induced by hypoxia and urinary L-
FABP excretion is strongly correlated with ischemic time in transplanted 
kidneys.116   This relationship is presumably driven by an HIF-1α response 
element in the promoter region of L-FABP.126  PPAR-α is also a potent 
upregulator of L-FABP gene expression, and this has been used in animal 
models of AKI to attenuate renal injury.117,118 Therefore, PPAR-α agonists such 
as fibrates represent an attractive therapeutic target in the prevention and 
treatment of acute kidney injury, although two recent observational studies found 
an association between fibrate use and acute kidney injury.127-129  
Similar to KIM-1, L-FABP is a highly accurate classifier of established AKI, even 
in the heterogenouse ICU population, among whom it had an AUC of 0.80 (Table 




evaluated in numerous studies in the cardiac surgery population.  In the first such 
study, Portilla et al. found that urinary L-FABP concentration at the 4 hour post-
operative time point predicted AKI (area under the receiver operator 
characteristic curve of 0.81) in a cohort of 40 pediatric cardiac surgery patients.60  
Three other studies of adult cardiac surgery patients seemed to confirm the 
predictive power of L-FABP, with none reporting an AUC <0.76.131-133  The 
results of these and other studies were included in a meta-analysis by 
Susantitaphong et al., which found that L-FABP was a sensitive and specific 
predictor for the early diagnosis of AKI (sensitivity and specificity of 74.5% and 
77.6%, respectively).134 However, this study only included a total of 7 prospective 
cohort studies and noted that, while L-FABP is a promising AKI biomarker, there 
is a paucity of high quality literature regarding the predictive performance of 
urinary L-FABP.  In light of this, the recent publication by the TRIBE-AKI 
Consortium, which was not complete at the time of the aforementioned meta-
analysis, is disappointing.  This study, which is a much larger, multicenter trial 
than what had been previous published, found that L-FABP had an AUC of 0.71 
and 0.66 in children and adults, respectively.  In relation to NGAL, IL-18, and 
KIM-1, all of which have been evaluated in the same cohort, L-FABP did not 
appear to be useful in adult patients, although it was one of the better predictors 
in children.  In fact, the combination of IL-18 concentration at ICU arrival and L-
FABP concentration on day 2 had an AUC of 0.78 for predicting severe AKI in 









Few studies have been done investigating L-FABP in other settings.  Nakamura 
et al. reported that it was diagnostic of contrast-induced nephropathy at 1 day 
post-exposure.136  This same study also found that patients who developed CIN 
had elevated baseline urinary L-FABP levels, and pre-procedure L-FABP 
concentration was an independent predictor of CIN.  A prospective study in ICU 
patients found that urinary L-FABP concentration at ICU admission predicted the 
development of AKI within one week (AUC = 0.70).77  Finally, in a different study, 
the same investigators found that L-FABP concentration at ICU admission was a 
nearly perfect predictor of in-hospital mortality in patients with sepsis-associated 
AKI.137  While these results are promising, the prognostic significance of L-FABP 
in patients with established AKI has not been adequately addressed and should 
be the focus of future research. 
Perspectives on AKI Biomarker Research 
Clearly novel AKI biomarkers have provided mechanistic insights into the 
molecular processes underlying AKI.  However, early enthusiasm regarding the 
predictive power of these biomarkers has been dampened by the results of larger 
prospective studies, particularly by the results of the TRIBE-AKI Consortium 
study.  Consequently, none of these biomarkers has supplanted serum creatinine 
in clinical use, and it remains unclear if any will attain widespread clinical use in 
the near future.  Additionally, there is a significant gap in the amount and quality 
of research that has been conducted on early markers of AKI and prognostic 
prediction, yet the identification of high risk groups is clearly important, both 




criteria.  The latter seems especially important given the increasing awareness of 
community-acquired AKI and the significant numbers of patients who present 
with AKI on hospital admission.  Therefore, novel renal injury biomarkers are 





   





Acute kidney injury (AKI) is associated with a number of adverse outcomes.  
Epidemiologic studies have reported that the risk of adverse outcomes is 
proportional to the severity of AKI. 6, 138-140  Accurate identification of high risk 
patients with severe renal injury early in the disease could augment the efficacy 
of available interventions and improve patient outcomes. However, it is not 
possible to estimate the severity of AKI at an early time point, because AKI 
staging is based upon the magnitude of changes in serum creatinine and urine 
output, surrogates of glomerular filtration rate that do not change until after renal 
injury has occurred and only reach their peak or nadir late in the course of the 
disease.2,3,43  Therefore, the recent KDIGO clinical guideline for AKI highlighted 
the need for improved risk assessment for patients with established AKI.9      
Biomarkers of AKI could be used to evaluate the severity of AKI at an early time 
point in the disease as a guide for clinical decision-making.  They could also play 
a role in clinical trial design because biomarkers could be used to selectively 
enrich the study population with patients who have severe renal injury and are 
more likely to benefit from an experimental therapy, increasing the effect size of 
the intervention and the statistical power of the study.141,142  Many biomarkers 
have been proposed as early markers of AKI, to detect of AKI prior to increases 
in sCr.  These include NGAL, KIM-1, IL-18, Cystatin-C, L-FABP.54, 60, 84, 104, 143, 144   
However, few studies have been performed to evaluate the prognostic value of 
these biomarkers once AKI has been established by traditional criteria.  The 




demonstrated the suboptimal prognostic performance of these biomarkers.79-80  
The objective of the following work is to discover novel candidate prognostic 
biomarkers of AKI.   
Materials and Methods 
Human Studies 
Urine samples were obtained from a bank of samples collected by investigators 
in the Southern Acute Kidney Injury Network (SAKINet).  The SAKINet was 
formed in 2007 under the direction of the candidate’s mentor, John Arthur, MD, 
PhD.  It includes investigators at the Medical University of South Carolina, Duke 
University, George Washington University, University of Tennessee College of 
Medicine in Chattanooga, and Vanderbilt University.  Urine was collected post-
operatively from patients who had undergone cardiac surgery.  Samples were 
collected as early as possible after AKIN serum creatinine criteria were met, and 
all were collected within the first 72 hours after surgery.  Inclusion criteria were 
surgery of the heart or ascending aorta and development of AKI within 3 days of 
surgery. Subjects with baseline serum creatinine > 3.0 mg/dL were excluded.  
Prior to urine collection informed consent was obtained in accordance with the 
IRB-approved protocol at each institution. Samples were collected and stored 
using a rigorous standard operating procedure.  Most patients were catheterized 
and urine was collected preferentially from the Foley tube or the urometer and 
processed immediately.  Samples were centrifuged at 1,000 x g for 10 min and 
the supernatant was collected.  A reversible serine and cysteine protease 




samples at a concentration of 1 tablet for 50 mL of urine, and samples were 
stored at  -80°C  in polypropylene tubes that had been pre-washed with 100% 
acetonitrile to minimize contamination of the samples with plastic polymer.  For 
analysis urine samples were thawed in a 37°C water bath and kept on ice 
afterward. 
Animal Studies 
AKI was experimentally induced in rats (n = 6) and mice (n = 10), by glycerol 
injection and renal ischemia reperfusion injury, respectively.  7.5 ml/kg of 50% 
glycerol (in saline) was injected i.m. and rats were housed in metabolic cages for 
24 hour urine collection.  Renal ischemia reperfusion injury was performed in 
mice by bilateral renal pedicle clamping using a non-traumatic vascular clamp 
(85 g pressure; Roboz Surgical Instruments).  Briefly, mice were anesthetized 
with 3% isofluorane and given buprenorphine s.c. (0.05 – 0.1 mg/kg).  Kidneys 
were exposed using a ventral surgical approach and the clamps were applied.  
Mice were kept on a heating pad and under a heat lamp to maintain body 
temperature throughout the procedure.  Ischemic time was 16 minutes and the 
reperfusion of the kidney was visually documented.  Afterward, mice were 
housed in metabolic cages and urine was collected for 16 hours.    
Proteomic Analysis 
A 100 μL aliquot of urine obtained from each human and animal subject was 
used for proteomic analysis. 100 μL of 0.2% Rapigest SF surfactant (Waters) in 
100 mM ammonium bicarbonate was added to the samples to improve digestion 




final concentration ) and heated to 60°C for 30 min.  After cooling to room 
temperature, proteins in the samples were alkylated with iodoacetamide (final 
concentration of ) and incubated at room temperature in the dark for 30 min.  
Samples were digested with trypsin overnight (10 μg added to each sample) at 
37°C.  The digestion was stopped by sample acidification via the addition of 750 
μL of 0.1% formic acid to the samples (approximately 3 volumes).  Each digested 
sample was pre-fractionated by offline reversed phase solid phase extraction 
(SPE) using Strata-X (Phenomenex; 30 mg/mL) SPE cartridges.  The SPE 
cartridge was activated and equilibrated with 1 mL of methanol and 0.1% formic 
acid, respectively.  The sample was then loaded onto the SPE cartridge and 
serial elutions using increasing concentrations of acetonitrile in 0.1% formic acid 
were performed.  After elution, sample fractions were dried in a centrifugal 
vacuum concentrator.  For liquid chromatography tandem mass spectrometry, 
samples were reconstituted in mobile phase A (98% water, 2% acetonitrile, 0.1% 
formic acid), and each sample fraction was then individually analyzed using LC-
MS/MS using an Eksigent 2D+ nanoHPLC in-line with an AB SCIEX Triple ToF 
5600 mass spectrometer.  Samples were loaded onto a 1 or 2 cm Acclaim 
PepMap 100 nanotrap column (Thermo Scientific; 100 μm ID x 1 or 2 cm, C18, 5 
μm, 100 Å).  Sample fractions were then eluted from the nanotrap column using 
a gradient of increasing percentage of mobile phase B (95% acetonitrile, 5% 
water, 0.1% formic acid) and separated using an Acclaim PepMap 100 analytical 
column (75 μm  ID x 15 cm, C18, 3 μm, 100 Å).  Tandem mass spectrometry was 




250 ms TOF MS accumulation time; 50 ms MS/MS accumulation time; 20 ions 
monitored per cycle; total cycle time 1.3 s; 4 s dynamic exclusion time after one 
occurrence; rolling collision energy.  The scanning windows for the TOF-MS and 
MS/MS were 300 – 1250 m/z and 55 – 2000 m/z, respectively.   
The above proteomic methods describe the general framework used in the four 
described experiments.  However, there were minor differences between 
experiments because the proteomic protocol was still in development at the time 
that these experiments were performed.  For example, the concentrations of 
acetonitrile used in the Stata-X SPE elution series differed from experiment to 
experiment.  A typical elution series included eluents of 10%, 15%, 20%, 25%, 
30%, 35%, 40%, 50%, and 60% acetonitrile in 0.1% formic acid.  Additionally, in 
some cases a 1 cm nanotrap was used for in-line sample separation, in other 
cases a 2 cm nanotrap was used.  Finally, the HPLC gradient used for in-lin 
sample separation differed between experiments, but generally was a two-step, 
continuous gradient increasing from 5% mobile phase B to 80% mobile phase B 
over a period of 40 to 60 minutes.  It is important to note that while these are 
differences between the four proteomics experiments, all samples within an 
experiment were treated in the same way.   
Protein Identification and Quantification.  
Acquired spectra (.wiff files) were converted to the MGF format using the AB 
SCIEX converter (version 1.1 beta). MGF files from all the fractions of each 
sample were merged and searched against the appropriate database using the 




this was the 2011_6 release of the Human UniProtKB/Swiss-Prot database 
(20,127 entries) with addition of the common contaminants (112 entries). 
Carbamidomethyl (C) was selected as a fixed modification, and oxidation (M) and 
deamidation (NQ) were selected as variable modifications. Monoisotopic masses 
were used, and the error tolerances were 10 ppm and 0.5 Da for peptides and 
MS/MS fragments, respectively. Mascot search results were loaded into Scaffold 
(Proteome Software, Inc), which used the Peptide Prophet and Protein Prophet 
algorithms to validate peptide and protein identifications. The relative abundance 
of identified proteins was determined using Scaffold quantitative values (a type of 
normalized spectral count) of identified proteins. 
Statistical Analysis 
Within each experiment, differentially abundant proteins were identified using the 
Wilcoxon Rank-Sum test, since it has been reported as a robust statistical test for 
biomarker discovery studies with small sample sizes.145  Correction for multiple 
comparisons was not used.  Mean fold change between the two experimental 
groups was calculated, and the MFC was plotted against the -log10(p-value), in 
order to enhance selection of candidate biomarkers.        
Results 
Early AKI Study 
In order to describe changes in urine protein abundance that occur early in the 
course of AKI, the urinary proteome of patients who developed severe AKI 
(defined as AKIN stage 3) after cardiac surgery (n=4) was compared to that of 




sample collection in was 9.6 hrs post-operatively, and at the time of sample 
collection, two of the AKI patients did not have elevated serum creatinine (sCr) 
meeting AKIN criteria for diagnosis of AKI.  There were no statistically significant 
differences between the two groups with respect to demographic variables, type 
of surgery, use of intraoperative cardiopulmonary bypass, bypass time, pre- 
operative/baseline sCr, sCr at the time of sample collection, and the time of 
sample collection.   A complete description of patient characteristics is shown in 
Table 2-1. A total of 230 proteins were identified with no false identification 
(calculated protein false discovery rate <1%).  Of these 109 proteins were unique 
to the AKI group (i.e. the protein was identified in ≥1 sample in this group, but not 
identified in any sample from the other group); 27 proteins were unique to the No 
AKI group (Figure 2.1a).  However, no proteins were consistently observed in 
one group but not detected in the other group (defined as identification of the 
protein in ≥3 samples of one group, but 0 samples in the other group).  Because 
of its significance to experiments that will be described later, it is noteworthy that 
angiotensinogen was detected in the urine of 2 of the 4 AKI patients, but none of 
the patients without AKI.  The two patients who did have detectable 
angiotensinogen had already met diagnostic criteria for AKI based on the 
magnitude of increased sCr that had already occurred at the time of sample 
collection.  Four proteins were identified which had P< 0.05: uromodulin, CD59 
glycoprotein, kinninogen-1, and vesicular integral-membrane protein VIP36.  The 
distribution of mean fold change and p-value for the identified proteins is 




         
Table 2-1 Characteristics of patients used in the discovery phase proteomics 
studies comparing severe AKI to No AKI 
 No AKI AKI P 




 25% (1) 0% (0) 1 
Caucasian
a
 100% (4) 75% (3) 1 
Age (yrs)
b
 63.8 ± 3.9 55.3 ± 12.2 0.34 
Weight (kg)
b
 100.4 ± 8.3 104.9 ± 8.3 0.67 
Sample Collection Time (hrs post-op)
b




 100% (4) 25% (1) 0.14 
Valve Replacement
a
 0% (0) 0% (0) 1 
CABG + Valve Replacement
a
 0% (0) 0% (0) 1 
Other Surgery
a
 0% (0) 75% (3) 0.14 
Bypass
a
 75% (3) 100% (4) 1 
Bypass Time (min)
b
 134.3 ± 32.1 147.3 ± 76.2 0.86 
Serum Creatinine (mg/dL) 
Pre-Op Value
b
 1.0 ± 0.3 1.5 ± 0.3 0.11 
At Sample Collection
b
 1.2 ± 0.3 1.9 ± 0.5 0.06 
Maximum Post-Op Value
b
 1.3 ± 0.3 4.8 ± 1.9 0.03 
Outcomes 
Days to Max sCr (from surgery)
b
 1.0 ± 0.8 3.0 ± 1.2 0.06 
RRT
a
 0% (0) 25% (1) <0.01 
Death
a
 0% (0) 25% (1) 0.06 
a
Percentage and n; 
b
Mean ± SD 
Groups were compared using Fisher’s Exact test for categorical variables and the 

















Figure 2-1. Urinary proteomic analysis of patients who either developed 
severe AKI after cardiac surgery or did not.  Liquid chromatography 
tandem mass spectrometry was used to identify and quantify urinary 
proteomic changes during AKI.  (A) Venn diagram showing the number of 
identified proteins by group.  Red represents the group with AKI; blue 
represents the group without AKI.  (B) Volcano plot shows the mean fold 
change in protein abundance between the two groups versus the statistical 
significance.  Smaller p-values are larger due to the transformation.  Data 
points above the dotted line have P< 0.05. 
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the combined data of this and three other proteomics experiments, the complete 
dataset is presented in Appendix A.  
Renal Replacement Therapy 
In order to identify candidate biomarkers of severe AKI, urine samples from 12 
patients who had undergone cardiac surgery and developed post-operative AKI 
were analyzed by liquid chromatography tandem mass spectrometry.  Six of 
these patients developed severe AKI requiring renal replacement therapy (RRT); 
six patients developed mild AKIN stage 1 AKI.  There were no statistically 
significant differences between the two groups with respect to demographic 
variables, urine sample collection time, use of cardiopulmonary bypass, bypass 
time, type of surgery, preoperative/baseline serum creatinine (sCr), and sCr at 
the time of sample collection.  A complete description of patient characteristics is 
shown in Table 2-2. 
A total of 343 proteins were identified with a false discovery rate of 1.9%.  Of 
these, 59 proteins were unique to the RRT group (i.e. they were identified in ≥1 
patient in the RRT group but none of the patients in the No RRT group), and 5 
proteins were unique to the No RRT group (Figure 2.2a).  Twenty-six proteins 
were identified as being differentially abundant between the two groups (P 
<0.05). The distribution of mean fold change and P value for the identified 
proteins is shown in the volcano plot (Figure 2.2b).  Several candidate 
biomarkers can be selected using the criteria of large mean fold change and low 
P value.  However, our objective was not to select candidate biomarkers using 
data from a single proteomics, but to collate data from several such studies.  




Table 2-2 Characteristics of patients used in the discovery phase proteomics studies 
comparing severe AKI requiring RRT to mild AKI 
 No RRT RRT P 




 33% (2) 33% (2) 1 
Caucasian
a
 100% (6) 100% (6) 1 
Age (yrs) 63.8 ± 7.9 72.5 ± 17.1 0.29 
Weight (kg) 75.9 ± 40.2 85.3 ± 37.5 0.33 




 50% (3) 33% (2) 1 
Valve Replacement
a
 17% (1) 17% (1) 1 
CABG + Valve Replacement
a
 33% (2) 17% 1) 1 
Other Surgery
a
 0% (0) 33% (2) 0.46 
Bypass
a
 67% (4) 67% (4) 1 
Bypass Time (min) 160.8 ± 67.0 165.0 ± 88.2 1 
Serum Creatinine (mg/dL) 
Pre-Op Value 13. ± 0.4 1.4 ± 0.3 0.76 
At Sample Collection 1.9 ± 0.4 2.6 ± 0.6 0.37 
Maximum Post-Op Value 2.1 ± 0.5 4.2 ± 1.4 0.006 
Outcomes 
Days to Max sCr (from surgery) 1.7 ± 1.0 4.8 ± 2.4 0.02 
RRT
a
 0% (0) 100% (6) <0.01 
Death
a
 0% (0) 67% (4) 0.06 
a
Percentage and n; 
b
Mean ± SD 
Groups were compared using Fisher’s Exact test for categorical variables and the 












Figure 2-2.  Urinary proteomic analysis of cardiac surgery patients who 
either developed severe AKI requiring renal replacement therapy (RRT) 
or mild AKI.  Liquid chromatography tandem mass spectrometry was used to 
identify and quantify urinary proteomic changes during AKI.  (A) Venn diagram 
showing the number of identified proteins by group.  Red represents the group 
that required RRT; blue represents the group that only developed mild, AKIN 
stage 1 AKI.  (B) Volcano plot shows the mean fold change in protein 
abundance between the two groups versus the statistical significance.  
Smaller p-values are larger due to the transformation.  Data points above the 




























Appendix A.  The combined data from this and other proteomics experiments is 
presented below.  Nevertheless, it is worthwhile to mention the results of one 
candidate biomarker, urinary angiotensinogen, at this point.  Of all the identified 
proteins in this experiment, it was the best discriminator based upon its large 
mean fold change (9.67-fold elevated in the RRT group) and low p-value (p = 
0.002).  Urinary angiotensinogen was undetectable in the 4 of the 6 patients in 
the No RRT group, and it discriminated with 100% accuracy between the two 
groups.          
Rat Glycerol Induced AKI Study 
In order to identify candidate biomarkers of AKI secondary to nephrotoxic 
causes, urine from rats (n = 3) in which AKI had been experimentally induced by 
glycerol injection was compared to that of vehicle injected controls (n = 3).  A 
total of 259 proteins were identified with no false discoveries (calculated FDR 
<1%).  Of the identified proteins, 33 were unique to the No AKI group and 48 
were unique to the AKI group (Figure 2-3).  However, only 37 of these proteins 
were consistently identified in the urine of the animals in AKI group (i.e. identified 
in all three group members but none of the other group).  These proteins are 
shown in Table 2-3.  Of note, of the 178 proteins shared between the groups, 
100 had a P value = 0.1, the lowest possible p-value given the small sample size 
of this experiment.  Of note, angiotensinogen was 10-fold elevated in the rats 
with AKI (P = 0.1), and it discriminated with 100% accuracy between the two 
experimental groups.  The complete list of identified proteins and group 



















                                                                           
 
Figure 2-3. Urinary proteomic analysis of rats with glycerol injection 
induced AKI compared to controls.  Liquid chromatography tandem mass 
spectrometry was used to identify and quantify urinary proteomic changes 
during AKI.  (A) Venn diagram showing the number of identified proteins by 
group.  Red (B) Volcano plot shows the mean fold change in protein 
abundance between the two groups versus the statistical significance.  
Smaller p-values are larger due to the transformation.  The dashed line 
represents P= 0.1.    
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Table 2-3. Urinary proteins uniquely identified in rats  
with and without AKI 
Protein Name 
Uniprot             
Acc. Num. 
Proteins Uniquely Identified in the Urine of Rats with AKI 
Fibrinogen alpha chain  P06399 
Protein NOV homolog  Q9QZQ5 
Creatine kinase M-type  P00564 
L-lactate dehydrogenase B chain  P42123 
Complement factor I  Q9WUW3 
Uteroglobin  P17559 
Cystatin-B  P01041 
Gastrotropin  P80020 
Hydroxyacid oxidase 2  Q07523 
Myosin-4  Q29RW1 
Sodium/potassium-transporting ATPase subunit 
alpha-1  
P06685 
Keratin, type II cytoskeletal 2 epidermal  Q6IG02 
Calreticulin  P18418 
Cartilage oligomeric matrix protein  P35444 
Alanine--glyoxylate aminotransferase 2, mitochondrial  Q64565 
Proteins Uniquely Identified in the Urine of Rats without AKI 
Phosphotriesterase-related protein  Q63530 
Dipeptidyl peptidase 2  Q9EPB1 
Pancreatic alpha-amylase  P00689 
Neprilysin  P07861 
Na(+)/H(+) exchange regulatory cofactor NHE-RF1 Q9JJ19 
Meprin A subunit beta  P28826 
Endothelial cell-selective adhesion molecule  Q6AYD4 
Na(+)/H(+) exchange regulatory cofactor NHE-RF3  Q9JJ40 
Ezrin  P31977 
Retinoid-inducible serine carboxypeptidase  Q920A6 
Glutamyl aminopeptidase  P50123 
Calbindin  P07171 
CD48 antigen  P10252 
Aquaporin-1  P29975 
Lysosomal alpha-glucosidase Q6P7A9 
Aflatoxin B1 aldehyde reductase member 3  P38918 
Beta-microseminoprotein  P97580 
Neuroplastin P97546 
Glutathione S-transferase alpha-1  P00502 




Table 2-3 continued 
Protein Name 
Uniprot     
Acc. Num. 
Proteins Uniquely Identified in the Urine of Rats without AKI 
Lysosomal acid phosphatase  P20611 
Protein FAM151A  Q642A7 



















Mouse Renal Ischemia-Reperfusion Injury Induced AKI Study 
To identify candidate biomarkers of AKI due to ischemic injury, urine from mice 
that had been subjected to renal ischemia-reperfusion injury (n = 5) was 
compared to that of sham operated controls (n = 5). This study identified 163 
proteins (calculated FDR = 3.4%), of which 56 were differentially abundant 
between the two experimental groups (P < 0.05).  Of these, only nine proteins 
were detected in the urine of all five mice with AKI but none of the sham operated 
controls.  Notably, angiotensinogen was one of the proteins identified only in the 
urine of mice with AKI.  These are displayed in Table 2-4, and the complete list of 
protein identifications is shown in Appendix A.  
Selection of Candidate Biomarkers 
Candidate biomarkers were selected based upon the combined data from the 
four proteomics experiments (Table 2-5).  However, the experiments were not 
given equal weight.  Since our objective was to identify prognostic biomarkers, 
we preferentially selected candidates based on the results of the RRT 
experiment, which compared patients with severe AKI requiring RRT to those 
with mild AKI.  As mentioned above, angiotensinogen was the best discriminator 
in this experiment.  Additionally, although it did not reach statistical significance, it 
was only observed in the urine of patients with AKI in the early AKI study.  
Similarly, angiotensinogen was observed in all 5 mice with renal ischemia-
reperfusion injury, but it was not detected in any of the sham operated controls.  




 Table 2-4. Urinary proteins uniquely identified in mice 
with AKI 
Protein Name 
Uniprot             
Acc. Num. 




Vitamin D-binding protein P21614 
Plasminogen P20918 
Polyubiquitin B P0CG49 
Gelsolin P13020 
Transthyretin P07309 















Figure 2-4.  Urinary proteomic analysis of mice with renal ischemia 
reperfusion injury induced AKI versus sham operated controls.  Liquid 
chromatography tandem mass spectrometry was used to identify and quantify 
urinary proteomic changes during AKI.  (A) Venn diagram shows the number of 
identified proteins by group.  Red represents the group with AKI; blue represents 
the group without AKI.  (B) Volcano plot shows the mean fold change in protein 
abundance between the two groups versus the statistical significance.  Smaller 
p-values are larger due to the transformation.  Data points above the dotted line 








 being markedly elevated in all three rats with AKI compare to controls (P = 0.1).  
Although the P value was >0.05, the lowest possible P-value for the Wilcoxon 
Rank-Sum test when n = 6 is 0.1, and so this difference was considered 
statistically significant.  Figure 2-5 summarizes the angiotensinogen 
measurements made in the four proteomics studies.   Qualitatively, 
angiotensinogen compared favorably with the well-established AKI biomarkers 
NGAL, KIM-1, and L-FABP (Table 2-5), suggesting that it could have similar or 
perhaps improved performance characteristics for the prediction of early AKI and 
AKI severity. 
Discussion 
A total of 22 novel candidate AKI biomarkers were identified using the combined 
results of four discovery phase proteomics experiments.  A relative strength of 
our study is the heterogeneity of the study groups.  The two human studies 
compared the urinary proteome of patients with early, severe AKI to that of 
patients without AKI (Early AKI Study) and the proteome of patients with early, 
severe AKI that eventually required renal replacement therapy (RRT) to that of 
patients with mild AKI (RRT study).  To complement these data, two studies of 
different animal models of AKI were conducted, renal ischemia reperfusion injury 
in mice and glycerol-induced AKI in rats.  The former has a similar mechanism to 
AKI after cardiac surgery, whereas the latter is a model of rhabdomyolysis-
induced AKI.  We hypothesized that we would have a greater probability of 
identifying translatable biomarkers by collating the data from these four 
















Figure 2-5. Point plots of urinary angiotensinogen abundance.  The data 
from the four previously described proteomics studies are displayed, showing 
the relative abundance of angiotensinogen in each of the individual subjects of 
the two experimental groups of each study.  For graphical representation, 
subjects in which angiotensinogen was not detected are represented as an 
open circle on the x-axis.  Statistical significance was determined with the 
Wilcoxon Rank-Sum test. MFC, mean fold change; Div/0, angiotensinogen 















































































each experiment.  In fact, we identified NGAL using this approach, which we 
believe validates our data.  It is important to acknowledge the limitations of 
discovery phase proteomics experiments.  Due to the small number of samples 
and multiple statistical comparisons that are made, there is a high probability of 
type I error and false discovery of candidate biomarkers.  To mitigate this 
probability, we used the non-parametric Wilcoxon Rank-Sum test for statistical 
comparison because it has been demonstrated to have a lower type I error than 
other tests.19  However we did not use an adjustment for multiple comparisons 
such as the Bonferroni or Benjamini-Hochberg corrections, largely because the 
studies were underpowered for such adjustments.  Instead, we selected 
biomarkers based on trends observed in the combined data of the four 
experiments.  Nevertheless, it is important to recognize that discovery proteomics 
experiments are only the first phase of a multistep biomarker identification 
workflow which has been proposed by Rifai et al (Figure 2-6).146  Phases which 
will need to be completed include qualification and verification, in which the 
differential abundance of the candidates is confirmed using a more targeted 
analytical approach, and verification, during which the biomarker is measured in 
populations other than the one used in the discovery phase  in order to evaluate 
its specificity.  In the final phase, validation, a clinical assay is developed and 
rigorously characterized.  These later phases will be addressed in subsequent 
chapters, which describe the qualification and verification of angiotensinogen, the 




    
 
 
     
Figure 2-6. Paradigm for understanding the biomarker discovery process.146  Four 
distinct phases are described: discovery, qualification, verification, and validation.  In 
each subsequent phase, the number of proteins being measured (analytes) decreases 
and the number of biological samples being evaluated increases.  There is also a shift 
from low throughput methodologies to more high throughput, targeted approaches.  Rifai 
et al. Protein biomarker discovery and validation: the long and uncertain path to clinical 









Chapter 3: Qualification of Urinary Angiotensinogen as a Prognostic 






Our previous study using urinary proteomic analysis identified a number of 
candidate prognostic biomarkers of acute kidney injury (AKI).  The most 
promising of these was urinary angiotensinogen.  Collated data from the four 
proteomic experiments showed that the relative abundance of urinary 
angiotensinogen was increased in every experimental state of each of the 
studies (see Table 2-4 and Figure 2-5) to a greater degree than other candidates, 
as determined by the mean fold change, and in 3 of the 4 experiments statistical 
significance was met.  Furthermore, the significance of elevated urinary 
angiotensinogen is intriguing from a mechanistic standpoint.  Angiotensinogen is 
the principal substrate of the renin-angiotensin system (RAS), a hormonal 
cascade that has pleiotropic effects in the kidney, including the regulation of 
hemodynamics, sodium reabsorption, aquaresis, cellular proliferation and 
apoptosis, fibrosis, and inflammation.147  Urinary angiotensinogen concentration 
is thought to reflect the level of activation of the intrarenal RAS.148  Thus, from a 
pathobiologic point of view, angiotensinogen is a logical prognostic biomarker. 
Materials and Methods 
Patients and Urine Samples 
Urine samples were selected from those banked by the Souther Acute Kidney 
Injury Network (SAKINet; see Chapter 2) in order to fit the criteria described 
below.  Patients had undergone cardiac surgery, and urine samples were 




criteria.3  Inclusion criteria were consent by the patient or appropriate surrogate, 
surgery of the heart or ascending aorta, and development of AKI (defined by the 
AKIN sCr criteria) within 2 days of surgery. Only subjects who had collection of 
urine within 48 hours after surgery were used in order to conform to the AKIN 
staging criteria and to attempt to eliminate confounding effects of events that 
were not directly related to the cardiac surgery.  The only exclusion criterion was 
a baseline sCr > 3 mg/dL. A total of 97 patients were included in this study.  
Urine samples from 10 of the patients used in this study were also used in the 
discovery phase proteomic analysis described in Chapter 2. Of the 97 patients 
enrolled, 79 were classified as AKIN stage 1 at the time of urine sample 
collection. 
Angiotensinogen ELISA 
The Human Total Angiotensinogen Assay Kit (Immuno-Biological Laboratories 
Co., Ltd.), a solid phase sandwich ELISA, was used according the 
manufacturer’s protocol to measure urinary angiotensinogen. Urine samples 
were diluted 1:8 in enzyme immunoassay (EIA) buffer provided by the 
manufacturer. One hundred μL of diluted sample was added to the appropriate 
well and incubated for 60 min at 37°C. The plate was then washed 7 times by 
pipetting 250 µL of the provided wash buffer into each well using a multichannel, 
repeating pipet. After drying the plate, 100 µL of 30x diluted HRP-conjugated 
anti-angiotensinogen antibody was added to each well and incubated for 30 
minutes at 37°C. The plate was washed 9 times as before and dried.  100 μL of 




min in the dark at room temperature. One hundred μL of stop solution was added 
to each well, and the absorbance was measured at 450 nm using a SpectraMAX 
340PC 96-well plate reader. The linear range of the assay is 0.31 to 30 ng/mL. 
Intra- and inter-assay variability (coefficient of variation) were calculated by 
measuring the standards and three selected biological samples in quadruplicate 
once, and in duplicate on all remaining plates. Values for intra- and interassay 
variability were 2.4% and 9.9%, respectively. Data were analyzed using Softmax 
Pro3.1.2. Samples whose values were above the upper limit of quantification for 
the assay were diluted 1:10 in EIA buffer and re-run on a separate plate.  If the 
value remained above the limit of quantification, a concentration of 20 ng/mL  
assigned to that sample.   
Urine Creatinine Determination. 
Urine creatinine was used to normalize the urine angiotensinogen concentration 
to account for biological variability in the concentration of urine.  This is 
accordance with the findings of Ralib et al. who reported that creatinine 
correction was appropriate and increased the prognostic predictive value of urine 
biomarkers of AKI.149  Values were reported as the ratio of angiotensinogen in 
ng/ml to creatinine in mg/ml (uAnCR, ng/mg). Urine creatinine was measured 
using the Jaffe assay.  Three μL of sample was combined with 100 μL of 1% 
picric acid (Sigma-Aldrich), 100 μL of 0.75M NaOH (Genomic Solutions), and 300 
μL distilled deionized H2O. Samples were incubated at room temperature for 15 
min and absorbance at 490 nm was measured using a SpectraMAX 340PC 96-





The primary outcome was worsening of AKI, defined as progression to a higher 
AKIN stage after the time of sample collection. Secondary outcomes were 
progression to AKIN stage 3, the need for renal replacement therapy (RRT) 
within 10 days of sample collection, progression to AKIN stage 2 or 3, 
progression to AKIN stage 3 or death, RRT or death, and discharge >7 days from 
the time of sample collection or in-hospital mortality. Outcomes were tested using 
the entire cohort and in a subset of patients classified as AKIN stage 1 at the 
time of sample collection. 
Statistical Analysis  
Count data were analyzed using the χ2 or Fisher’s exact test as appropriate.  
Continuous variables were analyzed using the Student’s t test or Mann Whitney 
U test when comparing two groups.  ANOVA or Kruskal-Wallis ANOVA on Ranks 
test and the post- hoc Dunn’s test for pairwise comparison were used to evaluate 
continuous variables when more than two groups were compared. Odds ratios 
(OR) were used to test the association of uAnCR with selected outcomes. 
Patients were stratified by uAnCR into quartiles, the effect of uAnCR on the risk 
of developing an outcome was tested by calculating the OR of the upper and 
lower quartiles and estimating the 95% confidence interval of the OR. Receiver 
operator characteristic curves were constructed to determine the predictive 
power of uAnCR. The area under the ROC curve (AUC) was used as an estimate 
of an overall accuracy of the biomarker. An AUC of 1.0 represents 100% 




than random chance. Univariate ROC curves were considered statistically 
significant if the AUC differed from 0.5, as determined by the z-test. Optimal cut-
offs were determined by selecting the data point that minimized the geometric 
distance from 100% sensitivity and 100% specificity on the ROC curve.150 
Additionally, cut-offs that maximized the positive likelihood ratio and minimized 
the negative likelihood ratio were reported since they could be useful in assigning 
high or low risk of adverse outcomes to a patient. Likelihood ratios of positive and 
negative predictive value were used since they are insensitive to changes in 
prevalence (unlike PPV and NPV) and can be used to infer post-test probability. 
Kaplan-Meier curves were used to visualize the relationship between uAnCR and 
length of stay. Patients who died were censored. The log-rank test was used to 
compare the curves, and the Holm-Sidak test was used for post-hoc pairwise 
comparison.  Category free net reclassification improvement was used to 
determine if addition of uAnCR to a multivariate logistic regression model for 
prediction of risk increased the ability of the model to predict worsening of AKI. 
First, a multiple logistic regression model (reference model) was created using 
the variables percent change in serum creatinine from baseline and Cleveland 
Score, a perioperative risk score that has been demonstrated to predict AKI 
outcomes after cardiac surgery.151, 152 Then, a new model was created which 
included uAnCR, in addition to these two variables.  Each patient’s probability 
(risk) of experiencing worsening of AKI after sample collection was calculated 
with both models.  The category free net reclassification index was calculated as 




predictive power gained by including uAnCR in the model.153, 154  Statistical tests 
were performed in either Matlab or SigmaPlot. 
Results 
We measured urinary angiotensinogen by ELISA and verified its ability to predict 
outcomes in patients who had developed AKI after cardiac surgery (n= 97). 
These patients were divided into three groups by maximum AKIN stage: stage 1 
(n= 59), stage 2 (n= 19), and stage 3 (n= 19). Of these, 79 patients (stage 1 n= 
59, stage 2 n = 10, and stage 3 n = 10) were classified as AKIN stage 1 (i.e. had 
less than a doubling of serum creatinine) at the time of urine sample collection.  
There were no statistically significant differences among the groups with respect 
to the following potential confounders: gender, race, age, use of intraoperative 
bypass, bypass time, pre-operative sCr, and type of surgery (Table 3-1). Since 
our primary objective was to identify a prognostic biomarker among patients with 
mild AKI, we performed a two analyses, one using the entire cohort and a second 
subset analysis using only patients who had not progressed beyond AKIN stage 
1 at the time of sample collection (n= 79). 
Urinary Angiotensinogen Concentration and AKI Severity 
Among all patients who had developed AKI of any stage at the time of urine 
sample collection, urinary angiotensinogen corrected for creatinine (uAnCR; ng 
angiotensinogen / mg creatinine) was correlated with both maximum sCr (r=0.49; 
p< 0.001) and maximum percent change in sCr (r= 0.29; p= 0.01), and uAnCR 




whole cohort and the subset of patients classified as AKIN stage 1 at collection 
(Table 3-1; Figure 3-1).  Post-hoc pair-wise comparison revealed a significant 
difference between the patients who developed AKIN stage 3 and those who 
reached a maximum of stage 1.  
Urinary Angiotensinogen and Adverse Outcomes 
We evaluated the ability of angiotensinogen to predict the primary outcome of 
worsening of AKI (defined as progression to a higher AKIN stage).  Comparing 
patients in the top quartile of uAnCR to those in the bottom quartile, the odds 
ratio for worsening of AKI was 5.0 (95% CI 1.16-21.46) in the whole cohort and 
4.64 (95% CI 1.02-21.0) in the subset of patients who were classified as AKIN 
stage 1 at collection.  Several secondary outcomes were also evaluated, 
including AKIN stage 3, the need for renal replacement therapy (RRT) within 10 
days, and the composite outcomes of development of AKIN stage 2 or 3, AKIN 
stage 3 or death, and RRT or death.  Ingeneral, patients with higher uAnCR were 
at increased risk of these outcomes (Table 3-2).  Receiver operator characteristic 
(ROC) curve analysis found that uAnCR was predictive of worsening AKI in both 
the whole cohort (AUC= 0.70) and in the subset classified as AKIN stage 1 at 
collection (AUC= 0.71).  It also predicted the other tested outcomes, with the 
exception of RRT in the subset of patients classified as AKIN stage 1 at 
collection (Figures 3-2, 3-3, and 3-4).  While the ROC curve for RRT prediction in 













Figure 3-1.  uAnCR increases with AKI severity.  Box and whisker plots showing the 
distribution of uAnCR by group in patients who developed AKI after cardiac surgery.  (A) 
Among patients who had AKI of any AKIN stage at the time of sample collection (n = 97), and 
(B) among the subset of patients who were classified as AKIN stage 1 at the time of sample 
collection (n = 79), uAnCr increased in a graded manner with AKI severity.  Box plots show 









percentiles.  AKIN stage groups were compared using the Kruskal-Wallis test (p-value shown 
in bottom right) and post-hoc Dunn’s test for pairwise comparison.  *, p< 0.05 when compared 










Figure 3-2.  uAnCR Predicts Worsening of AKI.  Receiver operator characteristic (ROC) 
curves demonstrate the ability of uAnCR to predict worsening of AKI after sample collection 
among (A) patients who were any stage AKI at the time of collection and (B) the subset of 
patients who were classified as AKIN stage 1 at collection.  Worsening of AKI was defined as 
progression to a higher AKIN stage.  A perfect biomarker would have an area under the ROC 
curve (AUC) of 1, whereas random chance has an AUC of 0.5.  The ROC curve was 





Figure 3-3.  Receiver operator characteristic (ROC) curves showing the 
predictive power of uAnCR for multiple adverse outcomes in patients 
who developed AKI after cardiac surgery.  The entire cohort (n = 97) was 







Figure 3-4. Receiver operator characteristic (ROC) curves showing the predictive 
power of uAnCR for multiple adverse outcomes in patients who developed AKI after 
cardiac surgery.  Only the subset of patients who were classified as AKIN stage 1 at the 
time of sample collection were included in these analyses (n = 79).  The outcome AKIN 
stage 2 or 3 is not reported here because it was previously reported as worsening of AKI in 




under powered since only eight patients required RRT in this group Notably, the 
predictive power for most outcomes among those patients classified as AKIN 
stage 1 at collection  appeared to be slightly augmented in comparison to the 
analysis including the entire cohort. In addition to the prediction of the renal and 
mortality outcomes, we noted a relationship between uAnCR and length of 
hospital stay. This relationship is visualized in survival curves plotting the time 
todischarge (defined as days after sample collection) of patients in the upper, 
middle or lower tertiles of uAnCR. Among all AKI patients and in the subset of 
patients classified as AKIN stage 1 at the time of collection, those patients with 
higher uAnCR concentrations had longer hospital stays (Figures 3-5a and 3-5b). 
ROC curve analysis indicated that uAnCR was predictive of longer length of stay 
defined as discharge >7 days from the time of sample collection or death ≤7 days 
from collection in both the whole cohort (Figures 3-3) and in the subset of 
patients who were classified as AKIN stage 1 at collection (Figure 3-4). Tables 3-
3 and 3-4 summarize the performance characteristics of uAnCR as a predictor of 
the tested outcomes in patients who had AKIof any stage at the time of sample 
collection and those who had not progressed beyond AKIN stage 1 at the time of 
sample collection, respectively. 
Net Reclassification Improvement 
We determined the ability of uAnCR to improve the prediction of worsening AKI 
of a clinical risk model. The clinical model was a multivariate logistic regression 





Figure 3-5. Survival curves showing the association of increased uAnCR and 
increased length of stay in cardiac surgery patients with post-operative AKI.  
Patients were stratified into tertiles by uAnCR.  Kaplan-Meier survival curves show 
that (A) in patients with any stage AKI at the time of sample collection ( n = 97), and 
(B) in the subset of patients classified as AKIN stage 1 at collection, patients with 
higher uAnCR had increased length of stay (defined as days to discharge from the 
time of sample collection.  The log-rank test was used to determine if the survival 
curves differed statistically (p-value shown), and the Holm-Sidak test was used for 














occurred at the time of sample collection and the patient’s Cleveland Clinic score, a 
perioperative risk score that predicts AKI severity after cardiac surgery.8,9  The ability of 
uANCR to improve the prediction by the clinical model was determined in both the entire 
cohort and in the subset of patients classified as AKIN stage 1 at the time of urine 
collection. When uAnCR was added to the clinical model, we found that it predicted 
worsening of AKI independently of the percent change in sCr and the Cleveland Clinic 
score (p= 0.02). Category free net reclassification improvement (cfNRI) was used to 
capture the added benefit of including uAnCR in the model. cfNRI compares each 
patient’s calculated risk for an outcome using a reference model to a new model 
(reference model plus uAnCR). Addition of uAnCR to the clinical model improved 
the ability to predict a patient’s risk of experiencing worsening of AKI in both the 
entire cohort and the subset of patients who were classified as AKIN stage 1 
(cfNRI= 0.457 and  0.428, respectively). To visualize the improvement in 
prediction, we constructed a risk assessment plot, as proposed by Pickering and 
Endre.7 This plot compares the sensitivity and 1-specificity of the reference and 
new models across the spectrum of calculated risk for each model.  Figure 3-6a 
and 3-6b  show that, in both the entire cohort and in the subset, the addition of 
uAnCR into the model resulted in patients who met the outcome (events) having 
a greater calculated risk, and patients who did not meet the outcome (nonevents) 
had a lower calculated risk. Therefore, both sensitivity and specificity were 





Figure 3-6. Risk assessment plots showing the improved prediction of worsening 
AKI when uAnCR is included in the model. Results from both (A) the entire cohort and 
(B) the subset of patients who were classified as AKIN stage 1 at the time of sample 
collection are shown. Of 97 patients in the whole cohort (A), 39 patients met the outcome 
worsening of AKI after sample collection, whereas in the subset analysis, 20 patients met 
the outcome. Two multivariate logistic regression models were created to predict risk of 
worsening of AKI after sample collection. The first model (reference) used percent change 
in sCr from baseline and Cleveland Clinic score created by Thakar et al. The second 
model included these variables plus uAnCR. Each patient’s probability (i.e., risk) of 
meeting the outcome worsening of AKI was calculated with both models. The sensitivity 
(proportion of events with a calculated risk equal to or above the defined threshold) and 1-
specificity (proportion of nonevents with a calculated risk below the defined threshold) was 






The urinary angiotensinogen/creatinine ratio (uAnCR) was elevated in patients 
who developed more severe AKI. Elevated uAnCR was associated with 
worsening of AKI, independent of changes in sCr and Cleveland Clinic score, 
and it was also associated with several secondary outcomes. The prognostic 
predictive power of uAnCR was improved when only patients who were classified 
as AKIN stage 1 at the time of sample collection were used in the analysis, 
indicating that angiotensinogen could be used to predict adverse outcomes 
among patients who have not yet developed severe AKI as measured by serum 
creatinine. Our data suggest that angiotensinogen could be used at the time of 
AKI diagnosis to assess the risk of adverse outcomes. This risk assessment 
could lead to improved outcomes by identifying high risk patients in need of 
therapeutic intervention, as was highlighted in the KDIGO Clinical Practice 
Guideline for Acute Kidney Injury.9 The guidelines suggest several interventions 
in patients with stage 2 and 3 AKI that are not recommended for patients with 
stage 1 AKI, including checking for drug dosing, considering renal replacement 
therapy, and considering ICU admission. Elevation in uAnCR could suggest a 
population of patients with stage 1 AKI who are likely to continue to worsen and 
could benefit from more intensive intervention.  While we did not directly compare 
the prognostic predictive power of angiotensinogen to that of other biomarkers, 
our results compare favorably with what has been reported in the literature for 
previously described AKI biomarkers. In a cohort of critically ill patients with AKI, 




the composite outcome of worsening of AKI or death for urine NGAL, KIM-1 and 
IL-18, respectively.79  In patients who developed AKI after cardiac surgery, 
Koyner et al. recently reported unadjusted AUCs of 0.58, 0.63 and 0.74 for urine 
NGAL, urine IL-18, and plasma NGAL, respectively, for the outcome of 
worsening of AKI.80  We found that uAnCR predicted this outcome with an AUC 
of 0.7 in a similar cohort of patients, and we confirmed that it predicted worsening 
of AKI in a subset of patients who were classified as AKIN stage 1 at collection 
(AUC = 0.71).  Thus, uAnCR, alone or in combination with other biomarkers 
could improve risk classification models in these patients.  
The results of the current study are limited by the heterogeneous etiologic nature 
of AKI (see the discussion on AKI etiology in Chapter 1), which was not taken 
into account in our study design.  This study was performed in post-operative 
cardiac surgery patients because both the timing and the severity of renal injury 
are readily determined in these patients, making them an ideal population for AKI 
biomarker research.  Additionally, the objective of this study was to confirm our 
findings from proteomic analysis (i.e. qualification of angiotensinogen).  However, 
it is plausible that the prognostic significance of urinary angiotensinogen 
concentration as an AKI biomarker could vary with the underlying etiology.  
Therefore, an important next step is verification of angiotensinogen as an AKI 
biomarker, during which we will attempt to confirm its association with adverse 
outcomes in AKI secondary to causes other than cardiac surgery.  This is 




prognostic predictive power of urinary angiotensinogen was tested in a critically 





   
Chapter 4: Qualification of Urinary Angiotensinogen as a Prognostic 





Discovery phase proteomic analysis identified urinary angiotensinogen as a 
promising AKI biomarker, and it was subsequently qualified in a retrospective 
cohort study designed to test its ability to predict adverse outcomes among post 
cardiac surgery patients with established AKI.  This study confirmed that elevated 
urinary angiotensinogen is associated with more severe AKI and increased risk 
of adverse outcomes such as worsening of AKI, the need for renal replacement 
therapy, and increased length of hospital stay.  However, as has been discussed 
in Chapter 1, AKI can be the result of a number of different precipitating factors, 
and it is likely that the performance characteristics of AKI biomarkers vary with 
the underlying etiology.  For this reason, an important step in evaluating novel 
AKI biomarkers is verification of their predictive power in patients with AKI 
secondary to diverse etiologies.   
The critically ill are the ideal population in which to test the effect of AKI etiology 
on biomarker performance, because of the heterogeneity of the causes of AKI 
and its associated comorbidities in these patients.  Common causes of AKI in the 
ICU population include sepsis, cardiac disease, liver disease, prolonged and 
unresolved pre-renal factors such as hypovolemia and hemorrhage, cardiogenic 
shock, radiocontrast, and rhabdomyolysis.14,15  The diversity of the underlying 
molecular mechanisms of these etiologies present a unique challenge to 
biomarker studies, and the heterogeneity of the ICU population tends to 
decrease the performance of AKI biomarkers compared to studies performed in 




because biomarkers which are correlated with AKI severity in this population are 
more likely to be mechanistically involved in AKI pathobiology on a fundamental 
level.  
Experimental Design 
In order to verify angiotensinogen as an AKI biomarker, a retrospective case-
control study was designed to evaluate the prognostic predictive power of urinary 
angiotensinogen in a population of critically ill, non-surgical patients with AKI.  
The composite outcome of the need for renal replacement therapy (RRT) or 
death was selected as the primary outcome since these are the most clinically 
relevant endpoints.  Secondary outcomes that were also evaluated included: 1) 
worsening of AKI, which was defined as an additional increase in serum 
creatinine (sCr) >0.3 mg/dL from the sCr at the time of the urine sample 
collection 2) worsening of AKI or the initiation of RRT; and 3) increased length of 
hospital stay (LOS), which was defined as hospital discharge >7 days from the 
day of sample collection or death ≤7 days from sample collection.  In comparison 
to the previous study on cardiac surgery patients, worsening of AKI was defined 
as an absolute increase in sCr after sample collection.  This approach was 
chosen because it is notoriously difficult to determine the baseline sCr value in 
critically ill patients, which impedes accurate staging using the AKIN or RIFLE 






Materials and Methods 
Patients and Urine Samples 
All patients (n = 45) had been admitted to the intensive care unit at the Medical 
University of South Carolina Hospital.  Patients either had AKI at ICU admission 
or developed AKI during their stay in the ICU.  AKI was defined according to the 
AKIN criteria.3  When possible, baseline sCr was defined as the most recent 
(within 1 month) value prior to the AKI episode.  When antecedent sCr values 
were not available, the lowest sCr observed during the patient’s hospital stay was 
used as the baseline.  Informed consent was obtained from the patients or their 
next of kin prior to urine sample collection, in accordance with our Institutional 
Review Board approved protocol.  The only exclusion criteria were initiation of 
renal replacement therapy prior to sample collection and non-consent.   
Urine samples were collected in collaboration with the MUSC Biomedical 
Research Bank. Patients for this study were selected retrospectively in order to 
perform a case-control study of ICU patients diagnosed with AKI at to the time of 
urine sample collection.  The primary outcome was the need for renal 
replacement therapy or death, and patients who had AKI at the time of sample 
collection but did not meet the primary outcome were selected as controls.  
Samples were collected at the time that the diagnosis of AKI was made.  If 
patients had AKI on admission, samples were collected immediately after 
admission.  Urine samples were processed according to a standard operating 




cOmplete, Mini, EDTA-free), centrifuged for 10 min at 1,000 x g and the 
supernatant was aspirated and stored at -80°C until the time of use.  Clinical data 
was obtained by retrospective chart review.   
AKI Etiology 
Etiology of AKI was determined by retrospective chart review and patients were 
assigned to one of four categories: pre-renal, ischemic ATN, sepsis-associated 
AKI, and other.  Pre-renal AKI was defined as an episode of AKI in the setting of 
hypotension or hypovolemia in which the patient’s sCr decreased to <150% of 
baseline within 48 hours after diagnosis.  Ischemic ATN was defined as severe, 
prolonged AKI following any event that compromises renal blood flow or oxygen 
delivery.  The specific events observed in our cohort included ruptured abdominal 
aortic aneurysm, cardiogenic shock, and congestive heart failure exacerbation.  
Patients for whom the etiology could not be determined or was multifactorial were 
included in the “other” category. 
Determination of Urinary Angiotensinogen-to-Creatinine Ratio   
Urinary angiotensinogen was measured using the Human Total Angiotensinogen 
Assay Kit (Immuno-Biological Laboratories Co., Ltd., IBL-America, Minneapolis, 
MN), a solid phase sandwich ELISA, according to the manufacturer’s protocol. 
Urine creatinine was measured using the Jaffe assay and used to correct the 
urine angiotensinogen concentration. Values were reported as the ratio of 
angiotensinogen in ng/ml to creatinine in mg/ml (uAnCR, ng/mg).   
Statistical Analysis 




uAnCR values of patients grouped by AKI etiology.  The Mann-Whitney U test 
was used when only two groups were compared.  Other continuous variables 
were compared using the Student’s t-test or Mann-Whitney U test.  Categorical 
variables were compared using the χ2 or Fisher’s Exact tests.  Logistic regression 
was used to determine the multiplicative odds ratio for a one standard deviation 
increase in uAnCR.  However, because uAnCR was not normally distributed, it 
was first log10 transformed for this analysis.  Receiver operator characteristic 
(ROC) curves were used to test the ability of uAnCR to predict outcomes.  The 
area under the ROC curve (AUC) was used as an estimate of overall accuracy of 
the biomarker.  ROC curves were considered statistically significant if the AUC 
differed from 0.5, as determined by the z-test. Optimal cut-offs were determined 
by selecting the data point that minimized the geometric distance from 100% 
sensitivity and 100% specificity on the ROC curve.24  Additional cut-offs were 
determined by selecting the points on the ROC at which the positive and 
negative likelihood ratios were maximized and minimized, respectively.  The 
Spearman’s correlation coefficient was used to determine the correlation 
between uAnCR and length of hospital stay.  Kaplan-Meier curves were used to 
visualize the relationship between uAnCR and length of hospital stay.  Patients 
who died were censored.  The log rank test was used to compare the curves.  
Cox regression was used to calculate the proportional hazard ratio for time to 
discharge comparing patients with high and low uAnCR (defined as > the median 
or ≤ the median of the cohort).  The Cox proportional hazard model included both 






Urine samples were obtained from patients with AKI in the intensive care unit  
(n=45).  At the time of sample collection, five patients were classified as AKIN 
stage 3, 12 patients as AKIN stage 2, and 28 patients as AKIN stage 1.  Baseline 
patient characteristics are described in detail in Table 4-1. In approximately one-
third of patients, the etiology of AKI could not be determined or was multifactorial 
(n= 16).  Sepsis-associated AKI was the most common established etiology 
(n=15), followed by pre-renal AKI (n= 8), and ischemic acute tubular necrosis 
(n=5).  Twenty-three patients met the primary outcome, the need for renal 
replacement therapy (RRT) or death.  Pre-renal AKI was significantly more 
common among the patients who did not meet this outcome (p = 0.01).  There 
were no significant differences between the group of patients who required RRT 
or died compared to those who did not with respect to age, race, gender, the day 
of sample collection (defined as days after the date that AKI criteria were met), 
baseline serum creatinine (sCr), sCr at the time of sample collection, or the 
percent change in sCr from baseline at the time of sample collection.  However, 
patients who met the primary outcome had lower rates of hypertension, diabetes 
mellitus, and the use of angiotensin converting enzyme inhibitors or angiotensin 
receptor blockers. 
Angiotensinogen Predicts RRT or Death  
Urinary angiotensinogen was elevated in the group of patients who met the 




Table 4-1. Characteristics of ICU patients used to verify the 
prognostic predictive power of urinary angiotensinogen as an 
AKI biomarker 
  
No RRT and   
Survival RRT or Death P 
n 22 23   
Age (yrs)
a
 62.9 ± 16.1 54.4 ± 17.6 0.1 
Caucasian 64% (14) 65% (15) 0.84 
Male 55% (12) 65% (15) 0.67 
AKI Etiology       
Sepsis 23% (5) 43% (10) 0.25 
Pre-renal 32% (7) 4% (1) 0.01 
Ischemic ATN 9% (2) 13% (3) 1 
Other 36% (8) 39% (9) 0.91 




1.15                                
(0.8-1.6) 





 2.1 ± 0.8 2.5 ± 0.8 0.06 
% Change in sCr
b
  
150%                         
(130-189%) 
200%                             
(150-257%) 
0.07 
Other Variables    




74.9                              
(70.4-86.8) 
68.6                                   
(64.5-84.1) 
0.08 
History of HTN 91% (20) 48% (11) 0.005 
History of Diabetes 
Mellitus 55% (12) 22% (5) 0.05 
History of ACE Inhibitor 
or ARB Use 48% (12) 17% (4) 0.03 
a
Mean and SD; 
b
Median and IQR; Categorical data are shown as 
percentage and n 
P-values are shown for the χ
2





ng/mg) compared to the group who did not (median uAnCR = 25.4 ng/mg IQR 
5.8 – 120.4 ng/mg; Figure 4-1A).  Elevated uAnCR was associated with an 
increased risk of meeting this outcome.  The multiplicative odds ratio for a one 
standard deviation increase in a patient’s uAnCR was 2.61 (95% CI 1.23 - 5.53).  
The receiver operator characteristic (ROC) curve for this outcome had an area 
under the curve (AUC) of 0.73 (Figure 4-1B; p = 0.01).  The optimal cut-off was 
34.76 ng/mg, at which the test had a sensitivity and specificity of 78.3% and 
54.6%, respectively.  The cut-off at which the test had the highest positive 
likelihood ratio (LR+ = 9.6) was 230.0 ng/mg.  Eleven of the 45 AKI patients had 
uAnCR values greater than 230.0 ng/mg, of which 10 met the outcome.  At this 
cut-off, the sensitivity and specificity of the prediction of RRT or death were 
43.5% and 95.5%, respectively. The positive predictive value of a value this high 
was 90.9%. Similarly, the lowest negative likelihood ratio of the test was 
achieved at a cut-off of 7.58 ng/mg (LR- = 0.14).  Eight patients had uAnCR 
values ≤7.58 ng/mg, of which 7 did not meet the outcome.  The test had a 
sensitivity and specificity of 95.7% and 31.8%, respectively at this cut-off. 
Worsening of AKI 
Elevated uAnCR was associated with an increased risk of worsening AKI after 
sample collection (Figure 4-2).  The ROC curve for this outcome had an AUC of 
0.77.  At the optimal cut-off, 34.76 ng/mg, the sensitivity and specificity were 
87.0% and 63.6%, respectively.  At the cut-off with the maximum LR+, 230.0 
ng/mg (LR+ = 4.31), the sensitivity and specificity were 39.1% and 90.9%, 




   
 
Figure 4-1. The urinary angiotensinogen-to-creatinine ratio in patients 
who met the outcome renal replacement therapy or death compared to 
patients who did not.  (A) Box and whisker plots show the median and 
interquartile range.  Error bars represent the 5th and 95th percentiles.  Groups 
were compared with the Mann-Whitney U test.  (B) Receiver operator 
characteristic curve was performed to evaluate the ability of uAnCR to predict 
the outcome renal replacement therapy (RRT) or death. A perfect biomarker 
would have an area under the ROC curver (AUC) of 1, whereas random 




sensitivity and specificity were 95.7% and 59.1%.  Eleven patients had uAnCR 
values above the cut-off of maximal LR+, 10 of whom met the outcome worsening 
of AKI.  Fourteen patients had uAnCR values below the threshold of minimal LR-
,of whom only one met the outcome. 
Length of Hospital Stay  
Among patients who survived to discharge (n = 26), uAnCR was correlated with 
days to hospital discharge (r = 0.57, p = 0.002).  Patients who had high uAnCR 
values (defined as >55.21 ng/mg, the median value) had an increased length of 
stay compared to patients who had low uAnCR (≤55.21 ng/mg).  The median 
LOS (defined as days after the time of sample collection) for these groups were 
22 and 7 days, respectively (Figure 4-3A; p = 0.01), and the AKIN stage adjusted 
hazard ratio for discharge was 0.367 (95% CI 0.17 – 0.91) for patients with high 
uAnCR compared to those with low uAnCR, indicating that uAnCR affects LOS 
independently of changes in sCr.  Elevated uAnCR was strongly associated with 
an increased risk of the composite outcome discharge >7 days from the time of 
sample collection or death ≤7 days from collection. The multiplicative OR for one 
SD increase in uAnCR was 3.31 (95% CI 1.36 - 8.04).  ROC curve analysis 
demonstrated that uAnCR was a strong predictor of this outcome (Figure 4-3B; 
AUC= 0.77).  At the optimal cut-off, 59.61 ng/mg, the sensitivity and specificity of 
the prediction of prolonged hospital stay were 60.6% and 83.3%, respectively.  
The cut-off at which the test had the highest positive likelihood ratio (LR+ = 5.5) 
was 123.5 ng/mg.  Sixteen patients were above this cut-off, of which 15 met the 






Figure 4-2. The urinary angiotensinogen-to-creatinine 
ratio as a predictor of the outcome worsening of AKI.  
ROC curve for the composite outcome worsening of AKI 
(defined as an increase in serum creatinine >0.3 mg/dL 







Figure 4-3. Urinary angiotensinogen-to-creatinine ratio and length of stay. (A) Patients 
were stratified into groups by urinary angiotensinogen-to-creatinine ratio (uAnCR).  Patients 
with uAnCR > the median for the cohort were classified as high (red line), whereas patients 
with uAnCR ≤ the median were classified as low (black line).  Patients who died were 
censored.  The median times to discharge (defined as days after sample collection) were 22 
and 7 days for the high and low uAnCR groups, respectively.  (B) ROC curve analysis was 
performed to evaluate the ability of uAnCR to predict the composite outcome discharge >7 




 96.5%, respectively. Similarly, the lowest negative likelihood ratio of the test was 
achieved at a cut-off of 3.31 ng/mg (LR- = 0.12).  Four patients had uAnCR 
values ≤ 3.31 ng/mg, of which three did not meet the outcome.  The test had a 
sensitivity and specificity of 97.1% and 25.0%, respectively at this cut-off. 
Urinary Angiotensinogen by AKI Etiology  
The urinary angiotensinogen/creatinine ratio (uAnCR) differed statistically by the 
underlying etiology of AKI (Figure 4-4).  Patients with AKI secondary to ischemic 
ATN had the highest median uAnCR (260.2 ng/mg, IQR 69.6 - 1213.2), followed 
by patients with AKI due to other or unknown causes, including multifactorial 
etiology (90.6 ng/mg, IQR 12.1 - 251.5), patients with sepsis-associated AKI 
(48.1 ng/mg, IQR 23.5 - 222.4), and patients with pre-renal AKI (11.3, IQR 5.2 - 
61.5).  Post-hoc pairwise comparison found a statistically significant difference 
between patients with ischemic ATN and patients with pre-renal AKI.  Patients 
were categorized into the dichotomous groups of pre-renal AKI and AKI of other 
etiologies (Figure 4-5). The median uAnCR for patients with pre-renal AKI (n=8) 
was 11.3 ng/mg (IQR 5.2 - 61.5) while the median for patients with AKI not 
classified as pre-renal etiology (n=37) was 80.2 ng/mg (IQR 22.7 – 259.2).  There 
was a statistically significant difference between the uAnCR values of this group 
compared to the group of patients with pre-renal AKI (p= 0.03).  
Discussion  
The prognostic predictive power of urinary angiotensinogen in the setting AKI 
after cardiac surgery was described in Chapter 3.  However, it was unclear if its 






Figure 4-4. Urinary angiotensinogen/creatinine ratio (uAnCR) by AKI etiology.  Patients 
who developed AKI in the ICU were grouped by the etiology underlying the AKI.  The median 
(black dot) and interquartile range (error bars) are shown.  *, p< 0.05 compared to ischemic 







Figure 4-5. Urinary angiotensinogen-to-
creatinine ratio (uAnCR) in pre-renal AKI 
compared to AKI of other etiologies.  The box 
and whiskers plots show the median and 





 percentiles.  Groups were compared 




cardiac surgery.  In the study described in this chapter, urinary angiotensinogen 
was measured in ICU patients who developed AKI secondary to diverse 
etiologies.  We found that elevated urinary angiotensinogen was associated with 
an increased risk of RRT or death, longer time to hospital discharge, and 
worsening of AKI after the time of sample collection, and that angiotensinogen 
was a strong predictor of these outcomes using ROC curve analysis. A potential 
confounding factor of our results is that urinary angiotensinogen was statistically 
decreased in patients with pre-renal AKI compared to those with AKI of other 
etiologies, and the former was more common in the group of patients who did not 
die or require RRT. Therefore, it is not clear if the relationship between elevated 
urinary angiotensinogen and this outcome is in fact driven by its association with 
etiologies that tend to produce more severe AKI.  Nevertheless, this would not 
negate the findings of this study because it is clinically important to distinguish 
between pre-renal AKI and AKI of other causes Pre-renal AKI typically is 
transient and resolves with fluid resuscitation, whereas other more severe forms 
of AKI do not. Pre-renal AKI is classically differentiated from AKI of other 
etiologies by FeNa <1% or FeUrea <35.155-157  However, FeNa can be 
confounded by diuretic use and is altered in the setting of sepsis, whereas 
FeUrea decreases with age and a multicenter trial reported that it was not 
diagnostic of transient AKI.158-160 Better biomarkers of pre-renal AKI are clearly 
needed.  In a recent study, Cystatin C, NGAL, IL-18 and KIM-1 were found to be 
elevated in ICU patients with pre-renal AKI compared to those without AKI, but 




Finally, an important limitation of this verification study is that it was a relatively 
small retrospective biomarker qualification study, and our findings will need to be 
confirmed in a larger prospective study.  Nevertheless, these data are 
encouraging and indicate that urinary angiotensinogen could have potential utility 






Chapter 5: Concomitant Elevation of Urinary Angiotensinogen and 





Epidemiologic studies have reported that the risk of adverse outcomes is 
proportional to the severity of acute kidney injury (AKI). 6, 138-140  Accurate 
identification of high risk patients with severe renal injury early in the disease 
could augment the efficacy of available interventions and improve patient 
outcomes. However, it is difficult to estimate the severity of AKI at an early time 
point, because AKI staging is based upon the magnitude of changes in serum 
creatinine and urine output, surrogates of glomerular filtration rate that do not 
change until after renal injury has occurred and reach their peak or lowest point 
later in the course of the disease.2,3,43  The recent KDIGO clinical guideline for 
AKI highlighted the need for improved risk assessment for patients with 
established AKI.9 Biomarkers of AKI could be used to evaluate the severity of 
AKI at an early time point in the disease as a guide for clinical decision-making. 
They could also play a role in clinical trial design because they could be used to 
selectively enrich the study population with patients who have severe renal injury 
and are more likely to benefit from an experimental therapy, increasing the 
statistical power of the study.141,142  Many biomarkers have been proposed as 
early markers of AKI which may be useful for the detection of AKI prior to 
increases in serum creatinine. These include NGAL, KIM-1, IL-18, Cystatin-C, 
and L-FABP.54, 60, 84, 104, 143, 144  While many studies have included an analysis of 
the the ability of these biomarkers to predict adverse outcomes, most have done 
so as a secondary analysis in cohorts designed to test early diagnostic capability.  




from such analyses may not be generalizable to patients with established AKI.  In 
support of this, the results of two recent studies that excluded patients without 
AKI have reported that NGAL, KIM-1 and IL-18 are substantially less accurate 
predictors of AKI progression and mortality than would be inferred from studies 
including patients without AKI, highlighting the need for other prognostic 
biomarkers.79,80 
We recently identified urinary angiotensinogen as a novel prognostic biomarker 
of AKI.161, 162 In the current retrospective cohort study we further evaluated the 
prognostic predictive power of angiotensinogen and its combination with renin 
and uromodulin.  Renin was evaluated because we hypothesized that it would 
predict AKI severity because it cleaves angiotensinogen in the rate-limiting step 
of the renin-angiotensin-system (RAS). Since renin and angiotensinogen 
concentrations reflect different components within the renal RAS, combinations 
of the two candidate markers may improve prediction. Uromodulin was chosen 
on the basis of discovery-phase proteomic analysis, which showed that it 
decreased during AKI.  This result was in agreement with recently published 
results of a pediatric AKI biomarker study which reported lower urinary 
concentration of uromodulin during AKI.163  Uromodulin potentially plays a 
renoprotective, anti-inflammatory role during AKI, and we hypothesized that 
patients with more severe AKI would have lower concentrations of uromodulin, 
and that the combination of elevated urinary angiotensinogen and decreased 
uromodulin would be an accurate predictor of AKI severity.164,164 Our findings 




subset of patients with stage 1 AKI with a very high risk (80%) of progression to 
stage 3 AKI or death. 
Materials and Methods 
Patients and Urine Samples 
Urine samples were obtained from 204 consecutively enrolled patients who had 
cardiac surgery at one of the SAKInet institutions between the dates of August 1, 
2008 and June 1, 2012.  This cohort included 74 samples included in our 
previously described study.161  Informed consent was obtained in accordance 
with the IRB-approved protocol at each institution. Samples were collected and 
stored using a standard operating procedure which included centrifugation, 
addition of protease inhibitors and storage at   -80°C. Urine samples were 
collected as early as possible after AKIN serum creatinine criteria were met, and 
all were collected within the first 72 hours after surgery. Inclusion criteria were 
surgery of the heart or ascending aorta and development of AKIN stage 1 AKI by 
creatinine criteria within 3 days of surgery. Subjects with ESRD, baseline serum 
creatinine > 3.0 mg/dL or AKI greater than AKIN stage 1 at the time of collection 
were excluded. Patients were followed until either time of death or hospital 
discharge, and were staged according to the maximum increase in serum 
creatinine using the AKIN classification system.3  Urine output criteria were not 
used in diagnosis or staging because urine output data was not available.   
Measurement of Biomarkers 
Urine samples were thawed at 37°C and urinary angiotensinogen was measured 




manufacturer’s protocol. Urinary renin was measured using a sandwich ELISA (R 
and D Systems) according to the manufacturer’s protocol. Urine was diluted 
1:2000 and uromoduin was measured by ELISA (BioVendor).  All biomarker 
concentrations were corrected for urine creatinine (biomarker/creatinine ratio). 
Urine creatinine was measured using the Jaffe assay. 
Statistical Analysis 
Patients were grouped according to maximum AKIN stage and biomarker 
concentrations were compared using the Kruskal-Wallis test with post-hoc 
pairwise comparison. Univariate receiver operator characteristic (ROC) curve 
analysis was performed to determine if Cleveland Clinic score, percent increase 
in serum creatinine from baseline, the urinary angiotensinogen/creatinine ratio 
(uAnCR), and the urinary renin/creatinine ratio (uRenCR) predicted the 
composite outcome development of AKIN stage 3 or 30 day mortality (AKIN 
stage 3 or death). Variables were considered predictive if the area under the 
ROC curve differed statistically from 0.5. Cleveland Clinic score and percent 
increase in serum creatinine were combined in a multivariate logistic regression 
model (clinical model) to predict the outcome. Biomarker concentrations were 
log10 transformed and added individually to the clinical model and category free 
net reclassification improvement and integrated discrimination improvement were 
used to determine if the addition of biomarkers improved prognostic predictive 
performance.153, 154  A classification tree was created using the four inputs 
(uAnCR, uRenCR, Cleveland Clinic score and percent change serum creatinine 




identify patients at high risk of meeting the outcome AKIN stage 3 or death. The 
tree was grown using Chi-squared Automatic Interaction Detection (CHAID), 
specifying at least 10 cases per parent node and 5 cases per daughter node. 
Nodes were split using the Pearson’s Chi-squared test if P <0.05. Bonferroni 
correction was applied to the P-values to adjust for multiple comparisons. 25-fold 
cross-validation was performed. Statistical tests were performed in SPSS and 
SigmaPlot.   
Results 
Patients Characteristics 
Urine samples were retrospectively analyzed from 204 cardiac surgery patients.  
Samples were obtained post-operatively at the time of diagnosis with AKI. All 
patients were classified as AKIN stage 1 AKI at the time of urine sample 
collection. Twenty-six patients progressed to AKIN stage 2, and 22 progressed to 
AKIN stage 3. Twenty-six patients met the primary outcome AKIN stage 3 or 
death. When patients were grouped by the primary outcome, there were no 
statistically significant differences in demographic variables, time of sample 
collection, or operative variables. However, compared to those who did not meet 
the outcome, patients who met the outcome had elevated pre-operative serum 
creatinine (median 1.1 versus 1.3 mg/dL; P = 0.02), serum creatinine (sCr) at 
collection (median 1.6 vs 1.9 mg/dL; P <0.001), and percent increase in sCr from 
baseline that had occurred at the time of collection (median 41% versus 64%; P 





Table 5-1. Characteristics of cohort of post-cardiac surgery patients 
enrolled in study 
 AKIN Stage 1 or 2 
and Survived 
AKIN Stage 3 or 
Death 
P 
n 178 26  
Age
b
 68 (59.0 – 76.0) 65.5 (58.0 – 79.0) 0.97 
Gender (female)
a
 32.6% (58) 38.5% (10) 0.71 
Race (Caucasian)
a











28.7% (51) 26.9% (7) 0.96 
CABG + Valve
a
 16.9% (30) 23.1% (6) 0.62 
Other
a
 7.9% (14) 15.4% (4) 0.37 
Bypass
a
 86.0% (153) 88.5% (23) 0.97 
Bypass Time
d
 141.0 (83.0 – 192.0) 159.5 (62.0 – 203.0) 0.66 
Collection Time (hr 
post-op) 
21.8 (19.2 – 43.0) 21.6 (19.2 – 33.6) 0.69 
Serum Creatinine (sCr mg/dL) 
Pre-Op sCr
d
 1.1 (0.9 – 1.3) 1.3 (1.0 – 1.8) 0.02 
sCr at Collection
d
 1.6 (1.3 – 1.9) 1.9 (1.6 – 3.1) <0.001 




41% (30% – 56%) 64% (35% – 80%) 0.003 
Outcomes 
Days to Max sCr
d,e
 2.0 (1.0 – 3.0) 5.0 (3.75 – 8.0) <0.001 




7.0 (6.0 -10.0) 14.0 (9.75 – 24.75) <0.001 
AKIN Stage 3
a
 0% (0) 84.6% (22) <0.001 




0% (0) 100% (26) <0.001 
Death
a
 0% (0) 34.6% (9) <0.001 
RRT
a
 0% (0) 50.0% (13) <0.001 
Statistical significance was determined by the χ2 test for categorical variables and 
the Mann-Whitney U test for continuous variables. 
aCategorical variables are reported as percentage (n). 
bType of surgery is reported as CABG only, Valve replacement only, CABG + 
Valve replacement, and other procedures. 
cCABG, coronary artery bypass graft 
dContinuous variables are reported as median (interquartile range). 




Biomarker Concentrations by AKIN Stage and According to Primary Outcome 
The urinary angiotensinogen/creatinine ratio (uAnCR) was correlated with both 
maximum serum creatinine (sCr) and the maximum percent increase in sCr (rho 
= 0.383 and 0.256, respectively; P < 0.001). Similarly, the urinary renin/creatinine 
ratio (uRenCR) was correlated with maximum sCr (rho = 0.392; P < 0.001) and 
the maximum percent increase in sCr (rho = 0.308; P <0.001). However, urinary 
uromodulin/creatinine ratio was not correlated with either maximum sCr or the 
maximum percent increase in sCr.  There was also a statistically significant 
correlation between uAnCR and uRenCR (rho = 0.341; P <0.001). Accordingly, 
there was a trend for both urinary angiotensinogen and urinary renin to increase 
with the maximum AKIN stage that a patient achieved (Table 5-2), and there was 
a statistically significant difference in uAnCR and uRenCR between patients who 
developed AKIN stage 3 AKI compared to those who only developed AKIN stage 
1 AKI. Uromodulin concentrations did not change with maximum AKIN stage, and 
so uromodulin was not investigated further.  When patients were grouped 
according to the primary outcome, development of AKIN stage 3 or death, those 
who met the outcome had higher uAnCR compared to those who did not (median 
and IQR of 30.84 and 10.75 to 89.95 compared to 96.7 and 38.23 to 457.34 
ng/mg; P < 0.001). Patients who met the primary outcome also had higher 
uRenCR than those who did not (median and IQR of 280.72 and 118.98 to 





Table 5-2. Distribution of urinary biomarker concentrations by maximum 
AKIN stage 
 AKIN Stage 1 AKIN Stage 2 AKIN Stage 3/death P
a
 




(10.72 – 82.42) 
36.39  









(2.5 – 6.14) 
4.01 
(2.61 – 7.83) 
5.09 





(113.88 – 564.34) 
406.79 




(335.43 – 2894.06) 
0.001 
Biomarker concentrations are reported as median (interquartile range) 
ap-value according to Kruskal-Wallis test 






Univariate Prediction of AKIN Stage 3 or Death 
Selected clinical variables and putative prognostic biomarkers were tested for the 
ability to predict the outcome AKIN stage 3 or death. Cleveland Clinic score 
(Figure 5-1a) and the percent change in sCr at the time of sample collection 
(Figure 5-1b) both predicted the outcome, having an area under the receiver 
operator characteristic curve (AUC) of 0.72 (95% CI [0.62, 0.83]) and 0.68 (95% 
CI [0.55, 0.82]), respectively. In comparison, angiotensinogen and renin were 
also moderately strong predictors (Figures 5-1c and 5-1d). The AUC of the 
urinary angiotensinogen/creatinine ratio (uAnCR) was 0.75 (95% CI [0.65, 0.85]). 
The AUC of the urinary renin/creatinine ratio (uRenCR) was 0.70 (95% CI [0.57, 
0.83]).  Additionally, the prognostic predictive power of these variables was 
evaluated in the subset of the cohort (n = 81; data not shown) that were classified 
as RIFLE-R at the time of collection, since it has been reported that this criterion 
has a lower false positive rate than AKIN stage 1 for diagnosis of AKI.  
Compared to the entire cohort this analysis found little difference in the ability of 
uAnCR, uRenCR, and Cleveland Clinic score to predict AKIN stage 3 or death, 
whereas the predictive power of the percent increase in serum creatinine was 
substantially improved.     
Multivariate Prediction of AKIN Stage 3 or Death 
A model including relevant clinical variables and biomarkers was created to 
predict the outcome AKIN stage 3 AKI or death. First, Cleveland Clinic score and 







 regression model. This clinical model had an AUC = 0.79 (95% CI [0.69, 0.88]) 
for the outcome (Figure 5-2). Then uAnCR and uRenCR were added stepwise to 
the clinical model to determine the incremental increase in the accuracy model 
gained by the addition of each biomarker (Table 5-3).  When uAnCR was added 
to the clinical model, the AUC improved to 0.85 (95% CI [0.78, 0.92]; P = 0.01 
compared to clinical model; Figure 5-2). This was the result of augmented 
sensitivity and specificity (Figure 5-3a and 5-3b).  The category free net 
reclassification improvement (cfNRI) for addition of uAnCR was 0.67 (95% CI 
[0.26, 1.09]; P = 0.001; Figure 5-4a and 5-4b), and the integrated discrimination 
improvement (IDI) was 0.06 (P = 0.09).  Although the IDI did not reach statistical 
significance, the median calculated risk of the event group increased significantly 
following addition ofuAnCR to the model  from 0.22 to 0.26 (P = 0.04).  In 
contrast to uAnCR, the addition of uRenCR to the clinical model did not improve 
the area under the ROC curve (AUC = 0.79 95% CI [0.69, 0.89]; Table 5-3).  
Although the IDI (0.02; P = 0.26) was not statistically significant, there was an 
improvement in risk reclassification (cfNRI 0.52 95% CI [0.10, 0.93]; P = 0.01; 
Table 5-3; Figure 5-4c and 5-4d).  Addition of uRenCR to a three variable model 
that included Cleveland Clinic Score, percent increase in sCr, and uAnCR did 
improve the accuracy of the model (cfNRI = 0.55 95% CI [0.14, 0.96], P < 0.01), 
although the IDI was 0.01 (P = 0.38) and there was no improvement in the AUC 
of the ROC curve (AUC = 0.85 95% CI [0.77, 0.92]; Table 5-3; Figure 5-4e and 5-
4f).  This marginal increase in the in the discriminative slope resulted in more 













 Figure 5-2. Multivariable Prediction Models for AKIN Stage 3 or Death.  Receiver 
operator characteristic (ROC) curves are shown for the Clinical Model (CM; includes 
Cleveland Clinic Score and percent increase in serum creatinine from baseline), the 
clinical model plus creatinine-corrected urine angiotensinogen (CM + uAnCR), and 
the clinical model plus creatinine-corrected urinary angiotensinogen and renin (CM 






Figure 5-3. Risk assessment plots showing the incremental changes in sensitivity and 
specificity resulting from stepwise addition of angiotensinogen and renin to the clinical 
model.  Addition of angiotensinogen to the clinical model improved sensitivity and 
specificity.  Subsequent addition of renin to the model resulted in a gain in sensitivity with 






increased sensitivity of the model in this range (Figure 5-3a). However, there was 
no improvement in specificity (Figure 5-3b).  Finally, the best cut-off for the ROC 
curve of the final model had a calculated sensitivity of 76.9% and a specificity of 
79.1% (PPV and NPV of 35.0% and 76.5%, respectively). 
Classification Tree 
Multivariate logistic regression is a powerful technique for evaluating the 
predictive power of biomarkers, but due to its complexity it is unlikely to be 
clinically useful in the setting of acute illness where the decision to intervene is 
especially time sensitive.  Additional limitations include the inability to identify 
subsets of patients in whom biomarkers under or over perform and insensitivity to 
potentially important nonlinear interactions between covariates in the model, both 
of which could be informative from a mechanistic perspective.   Therefore, we 
sought to create a simple algorithm that identifies patients at high risk of meeting 
the outcome AKIN stage 3 or death, which could be used to guide decision 
making. To accomplish this we chose to use Chi-squared Automatic Interaction 
Detection (CHAID) to grow a classification tree that assigned patients to risk 
groups by identifying interactions among the same variables that were previously 
used in multivariate logistic regression. In this analysis uAnCR, uRenCR, 
Cleveland Clinic score and percent change in serum creatinine were all 
statistically significant classifiers for the outcome (Figure 5-5). However, the 
model selected only urinary angiotensinogen and renin for use in prediction of 
the outcome. Using a cut-off of > 337.89 ng/mg for uAnCR, the model divided 






Figure 5-4.  Scatterplots showing the calculated risk of meeting the 
outcome AKIN Stage 3 or death.  The incremental changes in predictive 
accuracy gained by addition of angiotensinogen (A and B) and renin (C-F) was 
evaluated using category free net reclassification improvement (cfNRI) and 
integrated discrimination improvement (IDI).  These scatterplots are a visual 
representation of cfNRI and IDI.  Each data point represents the calculated 
risks of a single patient using a reference model (x-axis) and a model with an 









Figure 5-4. continued identity,indicating calculated risk that does not change 
with addition of a biomarker to the reference model.  The proportion of nonevents 
(patients who did not meet the outcome) below the line and the proportion of 
events (patients who met the outcome) is used to calculate the category free net 
reclassification improvement (cfNRI).  The magnitude of the changes in 
calculated risk, which is the vertical distance of a point from the line of identity, is 












Figure 5-5.  CHAID classification tree for the outcome AKIN stage 3 
AKI or death.  Chi-squared automatic interaction detection (CHAID) 
was used to grow the classification tree using the following variables: 
Cleveland Clinic score, percent increase in serum creatinine from 
baseline at the time of sample collection, urinary angiotensinogen 
(ng/mg creatinine; uAnCR), and urinary renin (pg/mg creatinine; 
uRenCR).  Pie charts represent the proportion of patients who met the 
outcome (events) or not (nonevents) at each node of the tree.  The 




% and 40.0% of the patients met the outcome, respectively. The intermediate risk 
group was then further subdivided into a low and high risk group using the cut-off 
of uRenCR >893.41 pg/mg. Applying the combination of these two cut-offs for 
uAnCR and uRenCR resulted in a group of 10 patients, 8 of whom met the 
outcome, yielding a sensitivity of 30.8% and specificity of 98.9%. The PPV and 
NPV of this model were 80.4% and 90.7%, respectively. Overall, the model 
correctly classified 90.2% of patients correctly, and the 25-fold cross-validation 
estimate of the risk of misclassification of events was 0.132 (SE = 0.024). ROC 
curve analysis found that CHAID model had an AUC of 0.91, and compared 
favorably with the multivariate logistic regression model (Table 5-4; Figure 5-5).  
Discussion 
In this retrospective cohort study, we measured the candidate AKI biomarkers 
angiotensinogen, uromodulin, and renin in spot urine samples that had been 
obtained from post cardiac surgery patients early after AKI diagnosis had been 
made on the basis of AKIN serum creatinine criteria. Of these patients, only 81 
had an increase in sCr >50% and none had an increase ≥100% at the time of 
collection. Both urinary angiotensinogen and renin predicted the composite 
outcome AKIN stage 3 or death, whereas uromodulin did not.  While our study is 
limited by the use of a composite outcome that relatively few (26 of 204) patients 
met, it was chosen because our objective was to identify patients at high risk of 
severe adverse outcomes. Selection bias cannot be entirely ruled out because of 




Table 5-4. Comparison of Multivariate Logistic Regression Model and 
CHAID Classification Tree 




0.85                        
[0.77, 0.92] 
76.9% 79.1% 35.0% 76.5% 
CHAIDc 
0.91                       
[0.87, 0.96]* 
30.8% 98.9% 80.4% 90.7% 
a




Cut-off specific performance characteristics shown are from the point on the ROC curve 
closest to the point of 100% sensitivity and specificity.  
c
CHAID, Chi-squared automatic interaction detection; cut-off specific performance 
characteristics shown are for the node representing uAnCR >337.89 ng/mg and uRenCR 
>893.41 pg/mg.   
*P = 0.02 compared to multivariate logistic regression model. 
Multivariate logistic regression and CHAID models were generated using the following 
variables: Cleveland Clinic score, percent increase in serum creatinine at the time of 
sample collection, urinary angiotensinogen/creatinine ratio (uAnCR), and urinary 







    
Figure 5-5. Multivariate receiver operator characteristic (ROC) 
curves for prediction of AKIN stage 3 AKI or death.  The ROC 
curves of two multivariate models, a CHAID classification tree (CHAID) 
and a multivariable logistic regression model (MLR) are shown.  Both 
models included four variables: Cleveland Clinic score, percent 
increase in serum creatinine from baseline at that time of sample 
collection, urinary angiotensinogen (ng/mg creatinine; uAnCR), and 
urinary renin (pg/mg creatinine; uRenCR).  Additionally, the ROC 
curves for angiotensinogen (uAnCR) and renin (uRenCR) are shown for 
comparison, although they were previously reported in Figures 1c and 
1d).  The CHAID classification tree model was the most accurate 





adjust for known confounders (Cleveland Clinic score and percent increase in 
serum creatinine at collection). We demonstrated that urinary angiotensinogen 
improved the predictive power of a clinical model that included these variables by 
using the net reclassification improvement and integrated discrimination 
improvement. These data confirm our previous findings regarding the prognostic 
predictive power of urinary angiotensinogen, although it is not a true validation 
study because approximately one-third of the patients used in this cohort (74 
patients, 10 of whom met the outcome) were included in our previous study 
(Chapter 3).161  We also found that elevated urinary renin is associated with 
severe AKI, and further addition of renin to the multivariate model appeared to 
improve sensitivity, indicating that the interaction between urinary 
angiotensinogen and renin concentrations is an important prognostic indicator.  
We believe that these findings are strongly suggestive of a role for the renin-
angiotensin system (RAS) in the pathobiology of AKI.  This notion is in 
agreement with data from animal models, and will be addressed in Chapter 7.     
Chi-squared automatic interaction detection was used to grow a classification 
tree to identify risk subgroups. Others have reported CHAID to be less accurate 
than multivariate logistic regression in ROC curve analysis.166  Nevertheless, we 
chose to use CHAID because of its relative simplicity and the ease of graphic 
representation of the results.  Additionally, CHAID offers some analytical 
advantages compared to logistic regression. Whereas logistic regression 
identifies independent predictors, CHAID is adept at identifying interactions 




identify subgroups in which covariates exert the greatest influence in a predictive 
model.166-168  Thus, CHAID can be used to generate or test hypotheses regarding 
the potential role of the relationship between variables and the outcome of 
interest, which is a particularly intriguing feature for testing combinations of 
biomarkers.167  The CHAID classification tree identified patients with concomitant 
elevation of both angiotensinogen and renin as the group with the highest risk for 
the outcome AKIN stage 3 or death, and found that clinical variables drove the 
predictive model when biomarker concentrations were low. We interpret these 
results as an indication that activation of the renin-angiotensin system could 
modulate AKI severity.  Importantly, this analysis found that angiotensinogen was 
a stronger predictor than renin, and renin was not a useful predictor when 
angiotensinogen was below 337.89 ng/mg. This is congruent with our hypothesis 
that renin improves the predictive accuracy of angiotensinogen based on the 
biological relationship between the two proteins, as angiotensinogen is the only 
known natural substrate for renin.169 Therefore, the CHAID model is also an 
informative guide for the potential use of the combination of these biomarkers in 
the event of discordance between the two.   
Urinary angiotensinogen and renin could be a useful AKI biomarker combination 
and could be used to guide clinical trial enrollment.  The PPV of the combination 
of uAnCR > 337.89 ng/mg and uRenCR >893.41 pg/mg was 80.4%, a 6.3-fold 
enrichment for the endpoint of stage 3 AKI or death (compared to 12.8% 
incidence).  This would increase the effect size of an intervention and result in an 




However, the trade-off is that a large number of patients would need to be 
screened. Using our cohort as an example, the ratio of enrolled to screened 
patients would be approximately 1:19 if the results from the CHAID model were 
used as inclusion criteria enrollment, since only 4.9% of patients had uAnCR and 
uRenCR values above these cut-offs.  Therefore, the cost of screening would 
need to be weighed against the potential benefits of enrichment (increased 
power and reduced enrollment), taking into account the assumed effect size of 
the intervention.  A more complete description of how biomarkers can be used to 













Acute kidney injury (AKI) is a common and serious disease that is associated 
with a number of adverse outcomes.  Conventional biomarkers (i.e. creatinine, 
blood urea nitrogen, and urine output) do not reliably predict the course of the 
disease from an early time point after renal injury, and are of limited prognostic 
utility.  AKI biomarkers that predict adverse outcomes are needed to guide 
clinical decision making.19, 47  Novel biomarkers of AKI such as neutrophil 
gelatinase-associated lipocalin (NGAL), interleukin-18 (IL-18), kidney injury 
molecule-1 (KIM-1), and liver-type fatty acid binding protein (L-FABP) have been 
proposed.54, 60, 84, 104, 143, 144  The TRIBE-AKI Consortium recently conducted a 
large, multicenter prospective trial, which reported disappointing results regarding 
the early predictive power of these biomarkers, highlighting the need for new 
discoveries in this important area of AKI research.63, 76, 90  
As described in the previous chapters, we have identified urinary 
angiotensinogen as a novel prognostic biomarker of AKI.  We have verified its 
prognostic predictive power in cardiac surgery patients and in the nonsurgical 
critically ill population.  However, in these studies, angiotensinogen was 
quantified using a sandwich ELISA, which can be negatively affected by the urine 
matrix, impeding accurate quantification.  Additionally, these studies did not 
evaluate other novel AKI biomarkers such as the ones mentioned above, and we 
do not know how angiotensinogen compares to these.  Finally, the discovery 
phase proteomics studies described in Chapter 2 identified other candidate AKI 




development of two parallel reaction monitoring mass spectrometry (PRM-MS) 
assays designed to quantify urinary angiotensinogen, the other candidate 
biomarkers, as well as the more established AKI biomarkers NGAL, KIM-1, and 
L-FABP.   
Tandem Mass Spectrometry and Protein Quantification 
Targeted tandem mass spectrometry techniques allow for highly accurate 
quantification of selected peptides and proteins.  First described over thirty years 
ago, selected reaction monitoring (SRM-MS) is the most simple of this family of 
techniques and is performed using a triple quadrupole mass spectrometer.13  
SRM-MS makes use of this instrument’s ability to select specific precursor and 
fragment ions for detection (Figure 6-1).170  Quantification is performed using the 
extracted ion chromatogram (XIC) of the precursor-fragment ion pair (called a 
reaction or transition).  The accuracy of quantification is improved through the 
use of stable isotope-labeled peptides, which have the same amino acid 
sequence as the target peptide, but are labeled on the C-terminus with C-13 and 
N-15 lysine or arginine.  Peak area ratio of the native-to-SIS XIC for the 
quantitypic transition is used for quantification, and can be compared to an 
external calibration curve for absolute quantification.  Additionally, as can be 
seen in Figure 6-1b, the SIS peptide has the same chromatographic retention 
time as the native peptide, which increases the specificity of the SRM-MS 
quantification.  A major advantage of the triple quadrupole platform is its speed, 
requiring approximately10 ms per transition.171  Thus this technique is highly 




allowed for the monitoring of several fragment ions per precursor ion, a technique 
called multiple reaction monitoring (MRM-MS).  MRM-MS provides improved 
specificity for the target peptide compared to SRM-MS, and it has become a 
popular method of protein biomarker quantification.172  This technique has been 
used to measure up to 67 proteins in a single 30 minute analytical run.173-175  
Newer generation hybrid mass spectrometers such as quadrupole ion trap and 
quadrupole time of flight instruments offer further advantages for peptide 
quantification due to their superior resolution and mass accuracy and are 
capable of running in a data dependent acquisition mode similar to MRM.  
However, an important distinguishing characteristic is that the mass analyzer of 
these instruments allows for detection of the all the fragment ions generated from 
a given precursor ion in parallel.  Peptide quantification based on all of the 
transitions generated during fragmentation has been termed parallel reaction 
monintoring (PRM-MS), and this method of quantification has been demonstrated 
to have improved linear range, reduced technical variability, and greater 
specificity for the target peptide compared to MRM-MS.176  Therefore, this 
relatively new technique is likely to become the new gold standard for protein 
quantification and an indispensable tool in the proteomics biomarker toolbox. 
Methods 
Patients and Urine Samples 
Urine samples were obtained from 204 consecutively enrolled patients who had 























































Figure 6-1. Schematic of selected reaction monitoring mass 
spectrometry.  (A) In SRM-MS mode peptides derived from a biological 
sample are chromatographically separated, are ionized by electrospray 
ionization, and enter the first quadrupole (Q1).  Only preselected precursor 
ions are allowed by the first quadrupole to enter the collision cell (Q2; second 
quadrupole).   After fragmentation a single fragment ion is allowed to pass 
into the third quadrupole (Q3) and to the detector for quantification using the 
peak area from the corresponding extracted ion chromatogram (XIC).  (B). 
Quantification with SRM-MS is accomplished using a stable isotopically –
labeled peptide that is identical in sequence to native peptide, but can be 
differentiated by its increased mass.  The ratio of the peak areas of the XICs 
of the two peptides is used for quantification and can be compared  to an 






of August 1, 2008 and June 1, 2012.  All samples used were included in our 
previously described study (Chapter 3).177  Informed consent was obtained in 
accordance with the IRB-approved protocol at each institution. Samples were 
collected and stored as previously described using a standard operating 
procedure which included centrifugation, addition of protease inhibitors and 
storage at   -80°C. Urine samples were collected as early as possible after AKIN 
serum creatinine criteria were met, and all were collected within the first 72 hours 
after surgery. Inclusion criteria were surgery of the heart or ascending aorta and 
development of AKIN stage 1 AKI by creatinine criteria within 3 days of surgery. 
Subjects with ESRD, baseline serum creatinine > 3.0 mg/dL or AKI greater than 
AKIN stage 1 at the time of collection were excluded.  Patients were followed 
until either time of death or hospital discharge, and were staged according to the 
maximum increase in serum creatinine using the AKIN classification system.3  
Urine output criteria were not used in diagnosis or staging because urine output 
data was not available.  For PRM-MS analysis, patient samples were grouped by 
the maximum AKIN stage attained by the patient, and a block randomization was 
used to divide the cohort into four batches of 40 samples consisting of 30 
patients who did not progress beyond AKIN stage 1, six patients who progressed 
to AKIN stage 2, four who progressed to AKIN stage 3. 
Selection of Peptides for Parallel Reaction Monitoring Assay 
With the exception of angiotensinogen, one tryptic peptide from each of the 
candidate biomarkers was selected for inclusion in the assay.  Peptides identified 




the assay.  When no suitable peptide could be identified from previous data, 
theoretical peptides were generated by in silico protein digestion (Peptide Mass) 
and an appropriate peptide was selected.178  Only peptides which were identified 
by BLAST alignment as unique to the protein of interest were used for PRM-MS.  
Stable isotope-labeled versions of these peptides (SIS peptides) were 
synthesized (New England Peptide), and were used during assay development 
and as internal standards for quantification of urine biomarkers.  These SIS 
peptides are C13- and N15-labeled on the C-terminus, and are only 
distinguishable from the endogenous (light) peptides by a shift in the mass of the 
precursor and fragment ions (y-ion series).   
Peptide Characterization 
To determine the predominant charge state of target peptides, an SIS peptide 
mixture was analyzed in information dependent acquisition mode using a 
Eksigent 2D+ HPLC in-line with an AB SCIEX Triple ToF 5600 mass 
spectrometer.  Theoretical collision energy values were calculated using the 
formula published by Kuzyk et al. and the formula suggested by the 
manufacturer.174  These values were used as a guide for empirical determination 
of optimal collision energy.  The elution profile of each peptide from the Strata-X 
solid phase extraction (SPE) cartridge used in our workflow was determined 
empirically.  The SIS peptide mix was spiked into a urine matrix and the SPE 
cartridge was washed with 5% acetonitrile 0.1% formic acid.  Serial elutions were 
performed using eluents of 10%, 15%, 20%, 25%, and 30% acetonitrile 0.1% 




most abundant fragment ion of each peptide precursor ion was calculated in 
each eluate to generate the elution profile.      
External Calibration Curve  
SIS peptides were brought to a concentration of 1 nmol/μL in 10% acetonitrile 
0.1% formic acid.  The peptide mix was then serially diluted and analyzed by 
liquid chromatography PRM-MS using an Eksigent 2D nano-HPLC and AB 
SCIEX Triple ToF 5600 mass spectrometer.  PRM-MS data were analyzed in 
Multiquant and the sum of three most abundant fragment ions of each peptide 
(except for the peptides for complement C4b and LFABP, for which only 2 ions 
were used) was used to generate an external calibration curve (standard curve) 
with 1/x weighting using OLS regression.     
Protein Quantification 
Batches of 40 samples were analyzed by the PRM-MS method outlined below.  
Within each batch three analytical blanks and a standard reference material 
(SRM) were also analyzed.  The SRM consisted of a pooled urine sample 
obtained from 5 patients with acute kidney injury after cardiac surgery.   
Trypsin Digestion 
Frozen samples were thawed in a 37°C water bath. A  50 μL aliquot of each 
sample was diluted 1:4 in 100 mM ammonium bicarbonate.  To estimate 
digestion efficiency, 40 ng of stable isotope-labeled angiotensinogen protein 
(C13- N15-labeled lysine and arginine residues; Origene) was spiked into each 
sample.  Proteins were denatured by the addition of 100 mM DTT and heating to 
60°C for 30 min.  Cysteine alkylation was performed by the addition of 0.5 M 




was added at a ratio of 1:20 with total protein and samples were digested for 12 
hr at 37°C.   
Solid Phase Extraction 
Following trypsin digestion samples were acidified by the addition of 3 volumes of 
0.1% formic acid.  At this time, a known concentration of SIS peptides was 
spiked into the samples to account for technical variability and to be used in 
downstream quantification.  Solid phase extraction (SPE) was used for sample 
clean up and preparation for liquid chromatography tandem mass spectrometry.  
Strata-X (Phenomenex) SPE cartridges were conditioned with 1 mL acetonitrile 
(Honeywell) and equilibrated with 1 mL 0.1% formic acid (Sigma).  Acidified 
sample digests were loaded on the SPE cartridge.  After waiting for 5 min, 
samples bound to the SPE cartridges were washed with 1 mL of 5% acetonitrile 
0.1% formic acid solution.  Sample elution was performed using 30% acetonitrile 
0.1% formic acid eluent.  Sample eluate was collected in Protein LoBind 
polypropylene tubes (Eppendorf), frozen at -80°C and dried in a centrifugal 
vacuum concentrator.   
Liquid Chromatography Parallel Reaction Monitoring Mass Spectrometry 
Dried samples were reconstituted by the addition of 50 μL of 10% acetonitrile 
0.1% formic acid followed by mild vortexing at room temperature for 20 min.  
Reconstituted samples were centrifuged at 15,000 x g 4°C for 15 min.  A 5 μL 
aliquot of supernatant was diluted 1:15 in 10% acetonitrile 0.1% formic acid in 
order ensure that peptides of higher abundance proteins (uromodulin, 
nonsecretory ribonuclease, myoglobin, superoxide dismutase, and liver fatty acid 




the supernatant was transferred directly into autosampler vials (Wheaton) and 
used to quantify lower abundance proteins.  Each sample was analyzed using 
two separate analytical runs, one optimized for low abundance proteins and one 
for high abundance proteins.  A 10 μL injection of undiluted sample was used for 
measurement of low abundance proteins, and a 5 μL injection of diluted sample 
was used for measurement of high abundance proteins.  Liquid chromatography 
was performed on a 2D Eksigent HPLC.  Briefly, samples were loaded onto a 2 
cm Acclaim PepMap 100 C18 nanotrap column (Thermo Scientific) and washed 
extensively with mobile phase A (98% water, 2% acetonitrile, 0.1% formic acid).  
Chromatographic separation was then performed using a continuous gradient on 
increasing percentage of mobile phase B (95% acetonitrile, 5% water, 0.1% 
formic acid) on a 15 cm Acclaim PepMap 100 C18 analytical column (Thermo 
Scientific).  Peptides were ionized using a nanospray ion source, and analyzed 
using an AB SCIEX Triple ToF 5600 mass spectrometer.  Parallel reaction 
monitoring data acquisition parameters include MS accumulation time of 150 ms, 
fragmentation only of masses corresponding the empirically derived m/z of each 
peptide/SIS peptide pair selected during assay design using empirically derived 
collision energy, and 100 ms of MS/MS accumulation time was specified.  The 
total cycle time for the data acquisition method was 2.15 s for low abundance 
proteins and 1.8 s for high abundance proteins.  The extracted ion 
chromatrogram (XIC) of the sum of no fewer than 2 precursor ion-fragment ion 




corresponding SIS peptide and external calibration curve  All PRM-MS data were 
analyzed in Multiquant (AB SCIEX).  
Assay Characterization 
A standard reference material (SRM), which was a pooled urine sample obtained 
from 5 patients who had developed AKIN stage 1 AKI after cardiac surgery was 
used as a standard reference material (SRM).  A 50 μL aliquot of the SRM was 
processed and analyzed with each batch of 40 patient samples.  The coefficient 
of variation of the calculated protein concentrations was used to assess 
interassay variability.  Analytical blanks were used to calculate the limit of 
detection (LOD) and lower limit of quantification (LLOQ) of the assay, as 
described by Mani et al. The distribution of the peak areas of the twelve blanks 
was determined, and outliers were identified using the upper and lower fences of 
a box plot (defined as 75th percentile + 1.5*IQR and 25th percentile – 1.5*IQR, 
respectively).  Blanks which fell outside of this range were deemed unreliable 
estimates of assay performance.  LOD and LLOQ were then calculated 
according the method described by Mani et al.172    
Statistical Analysis 
The primary outcome was the development of AKIN stage 3 AKI or death.  
Creatinine corrected molar concentration of target proteins was not normally 
distributed, and so comparison of biomarker concentrations between the group of 
patients who met the outcome and those who did not was performed using the 
Mann-Whitney U test.  Receiver operator characteristic (ROC) curve analysis 
was used to evaluate the ability of each biomarker to predict the primary 




biomarker concentration and risk of meeting the primary outcome.  Because a 
significant number of patients had calculated biomarker, biomarker 
concentrations were transformed into an ordinal scale (<LOD = 0, <LLOQ =1, 1st 
quartile = 2, 2nd quartile = 3, 3rd quartile = 4, 4th quartile = 5).  Ordinalized 
biomarkers were also combined in a backwards stepwise multivariate logistic 
regression model to identify independent predictors of the primary outcome.   
Goodness of fit was assessed with the Hosmer-Lemeshow, Pearson Chi-square, 
and Likelihood ratio tests.  Statistical Analysis was performed in SPSS (version 
21 and Sigma Plot (version 11).   
Results 
Patient Characteristics 
Urine samples collected from 157 patients who had developed AKI after 
undergoing cardiac surgery were analyzed using the PRM-MS assay that we 
developed.  All patients had developed AKI within 72 hours after surgery and 
were classified as AKIN stage 1 by serum creatinine (sCr) criteria at the time of 
sample collection.  Twenty-one patients met the primary outcome of development 
of AKIN stage 3 or death.  Patients who met the outcome were well-matched to 
those who did not with respect to demographic and intraoperative variables.  
However, sCr at the time of collection and the change in sCr from baseline were 
higher in the group of patients who met the outcome, and there was a trend 
toward higher pre-operative sCr  in this group.  A comparison of patients who met 










A total of 22 candidate biomarker were identified by discovery phase proteomic 
analysis (see Chapter 2, Table 2-4).  We attempted to design a PRM-MS assay 
using a single tryptic peptide to quantify each of the proteins, with the exception 
of angiotensinogen for which we selected three peptides (Table 6-2).  Peptides 
which had been identified during discovery proteomic analyses of human urine 
were screened to determine their suitability for inclusion in the assay.  In order to 
be included peptides had to have been unmodified, not contain any cysteine or 
methionine residues, not contain any missed cleavages, and be unique to the 
target protein.  Unfortunately, we could not identify suitable peptides for Secreted 
Ly-6/uPAR-related protein, Complement C3 and Hepcidin, so these candidate 
biomarkers were not be included in the assay.  The SIS peptides were analyzed 
in information dependent acquisition mode to ascertain their predominant charge 
state.  The peptides that were selected to quantify Thymosin Beta-4 and Insulin-
like growth factor binding protein 1 were not detectable during this analysis, 
indicating that they were either insoluble or failed to ionize well.  After the optimal 
collision energy was empirically determined for the remaining peptides, an 
external calibration curve was generated.  The sum of the intensities of the three 
most dominant fragment (y) ions was used for quantification, with the exceptions 
of the peptides for Complement C4-B and L-FABP, which only had two 
detectable y-ions.  The peptides for Profilin-1, Glutathione peroxidase-3, 
Lysozyme C, and Polymeric immunoglobulin receptor did not have linear 
standard curves, and so these were also excluded from the assay. In contrast, 12 

















linear range of the standard curve of 11 of these at attomolar concentrations. 
Therefore, the final assay contained 16 native/SIS peptide pairs representing 14 
proteins, including 3 established AKI biomarkers: neutrophil gelatinase-
associated lipocalin, kidney injury molecule-1, and liver-type fatty acid binding 
protein.    
We attempted to estimate the average abundance of each of the proteins in the 
assay because others have reported that the accuracy of quantification 
decreases when the SIS peptide spike differs from the endogenous peptide by 
greater than a factor of 10.174  A literature search returned estimates for CD59, 
myoglobin, KIM-1, L-FABP, and NGAL.  The concentrations of urinary 
angiotensinogen and uromodulin were estimated using the mode of the values 
obtained by ELISA in the experiment described in Chapter 5.  The molar 
abundance of the remaining proteins was estimated using exponentially modified 
protein abundance index (emPAI) values obtained from discovery phase 
proteomic analysis in Chapter 2, indexing them to ELISA measurements that we 
had previously made on angiotensinogen and uromodulin.  These estimates 
indicated that the target proteins spanned several orders of magnitude, which 
complicated our analysis because it was obvious that all of the proteins would not 
be in the linear range of the standard curve if a single sample injection were used 
(Table 6-3).  Therefore, we decided to adapt the analytical approach such that 
each sample was analyzed twice, once in undiluted form (that is reconstituted 
with the amount of volume equal to the starting sample volume) and once as a 




 Assay Performance: LOD, LLOQ and CV 
Assay performance characteristics for each target peptide are reported in Table 
6-4.  Unfortunately, many of the samples had values that were undetectable 
(below the limit of detection; LOD).  More samples had calculated values below 
the lower limit of quantification (LLOQ).  In some cases the target proteins were 
only observed in a very small percentage of patients (CD59), and KIM-1 and 
apolipoprotein A-IV was not detected in any samples.  Therefore, these proteins 
could not be evaluated.  The external calibration curves for CD59, and KIM-1 
were among the lowest quality included in the assay, which could explain the 
poor measurements made on these proteins.  In contrast, the large number of 
patients with apolipoprotein A-IV and values below the LOD was surprising given 
excellent calibration curve for this peptide, suggesting that either the endogenous 
protein is outside of the range of the assay or that this peptide is not observed 
due to ion.   
The coefficient of variation (CV) of the measurements made on the standard 
reference material (SRM) that was analyzed with each batch was used to 
estimate interassay variability.  Unfortunately, the CV could not be calculated for 
many of the proteins because the native peptide was undetectable in the SRM.  
This likely reflects a low concentration of the target proteins in the urine samples 
that were pooled to make the SRM.  Therefore, the technical variability of the 
assay could not be evaluated for several of the proteins.  To overcome this 
limitation in future studies, the SRM should include a spike of unlabeled peptide 









Angiotensinogen 0.188 fmol/μL 
Pigment epithelium derived protein 0.188 fmol/μL 
Antithrombin III 0.188 fmol/μL 
Complement C4-B 0.188 fmol/μL 
Apolipoprotein A-IV 0.188 fmol/μL 
Myoglobin 5.82 fmol/μL 
Proepidermal growth factor 0.188 fmol/μL 
NGAL 1.33 fmol/μL 
KIM-1 0.052 fmol/μL 
Uromodulin 71.7 fmol/μL 
CD59 282.0 fmol/μL 
L-FABP 63.3 fmol/μL 
Superoxide dismutase 71.7 fmol/μL 








that could be calculated were higher others have reported.174,175  This is likely 
due to a difference in study design.  We chose to digest and process the SRM 
concurrently with each batch, whereas others make an SRM batch which is 
digested and processed separately from the samples of each batch and is only 
analyzed concurrently with the samples.  Thus the CV that is reported here 
incorporates variability in each step of the workflow from digestion to instrumental 
analysis, whereas the use of an SRM batch only accounts for instrumental 
variability. 
 
Qualification of Candidate Biomarkers by Targeted Mass Spectrometry    
Because many patients had biomarker concentrations that were below the limit of 
detection for the assay, we compared the proportion of patients with biomarker 
concentrations above the LOD who met or did not meet the AKIN stage 3 or 
death (Table 6-5).  Patients who met the outcome were more likely to have 
urinary concentrations of L-FABP, superoxide dismutase [Cu-Zn], and myoglobin 
above the LOD of the assay, compared to patients who did not meet the 
outcome.  Next, the association of elevated biomarker concentration (not 
creatinine-corrected) and risk of development of AKIN stage 3 or death was 
determined using an ordinalized protein concentration scale that included the 
following cut-offs:  <LOD, >LOD but <lower limit of quantification (LLOQ), 1st, 2nd, 
3rd, and 4th quartiles above the LLOQ (Table 6-5).  Complement C4B, and CD59 
were excluded from this analysis because only a small number of patients who 












concentrations of angiotensinogen (OR = 1.56 95% CI [1.19, 2.05]), superoxide 
dismutase [Cu-Zn] (OR =1.89 95% CI [1.31, 2.73]), L-FABP (OR = 1.46 95% CI 
[1.01, 2.11]), and myoglobin (OR = 1.69 95% CI [1.16, 2.48]) were associated 
with an increased risk of meeting the outcome.  Finally, we evaluated the ability 
of creatinine-corrected biomarker concentrations to discriminate between 
patients who would meet the outcome and those who did not.  In order to 
complete this part of the analysis, the LOD of each biomarker was applied as a 
threshold such that patients who had biomarker concentrations below the LOD 
were made equal to the LOD.  The median concentrations of angiotensinogen, L-
FABP, and superoxide dismutase were higher in patients who developed AKIN 
stage 3 or died Table 6-6).  Receiver operator characteristic curve analysis found 
that all of these proteins were predictive of the primary outcome (Figure 2). 
Discussion 
A multiplex tandem mass spectrometric assay was developed to quantify 10 
candidate prognostic biomarkers of AKI, as well as angiotensinogen, NGAL, L-
FABP, and KIM-1.  Peptides for an additional 6 peptides from 6 other candidate 
biomarkers were evaluated for inclusion in the assay but did not perform well 
during the development phase and were excluded.  Future studies should 
attempt to quantify these proteins using different proteotypic peptides.  This 
assay was similar in design to PRM-MS assays that have been described, in that 
it utilized an analytical platform with a high resolution and mass accuracy, and so 
our data benefitted from enhanced precision compared to a conventional MRM-
MS approach.176  However, our assay was not a true PRM-MS assay because 




(although the entire fragmentation spectrum was collected).  This approach was 
chosen because it has been our experience with our instrument that lower 
abundance transitions introduce chemical noise and reduce the sensitivity of the 
measurement.   
Urine samples from a total of 157 cardiac surgery patients were analyzed and the 
concentrations of the 14 proteins were evaluated for prediction of the outcome 
AKIN stage 3 or death.  Disappointingly, many of the measurements that we 
made were below the lower limit of quantification (LLOQ) or the protein was 
undetectable.  There are several possible explanations for this including: 1) 
matrix effects that suppress the ionization of the target peptide, 2) poor digestion 
efficiency resulting in lower abundance of the target peptide, 3) protein 
modification that either reduces digestion efficiency or shifts the mass of the 
target peptide, and 4) low protein abundance that is below the range of the 
assay.  In the unique case of NGAL, the incorrect precursor ion was selected for 
fragmentation, and so no data could be acquired to quantify it.  This is a limitation 
of the study, because NGAL is a well-validated AKI biomarker and novel 
candidate biomarkers should be compared to it.  Despite these significant 
limitations, we attempted to draw a valid conclusion from the data by assuming 
that data points below the LOD were due to low levels of the endogenous 
protein, and so the LOD  was applied as a threshold to the data and all values 
<LOD were made equal to the LOD.   
Using this approach, we found that the candidate biomarkers angiotensinogen, 




Although we admit that the accuracy of our measurements must be viewed with 
caution because the assay was not thoroughly validated, we believe that the 
precision is sufficient for relative quantification and that our inferences are valid.  
This is evidenced by three confirmatory findings present in our data.  First, we 
found a good correlation between angiotensinogen values obtained by PRM-MS 
and those previously measured by ELISA, and the data obtained by PRM-MS 
showed that angiotensinogen predicted AKIN stage 3 or death with an AUC 
nearly equal to that obtained using ELISA measurements.  Similarly, we 
confirmed that uromodulin did not predict the outcome, which we had also 
previously found using an ELISA for quantitation.  Finally, we found that liver-type 
fatty acid binding protein (L-FABP), a well-established AKI biomarker, predicted 
this outcome that has been reported to be an excellent predictor of mortality in 
patients with sepsis-associated AKI.137   
These results are the first to report superoxide dismutase [Cu-Zn] and myoglobin 
as AKI biomarkers.  While these finding will need to be confirmed with a more 
well-validated assay, the prognostic significance of these proteins is congruous 
with our understanding of the role of oxidative stress in AKI.  Specifically, 
myoglobin, a heme-containing protein, can generate free radicals and is a known 
nephrotoxin.  It is plausible that higher concentrations of myoglobin in the urine 
would be associated with more severe renal injury.179  Conversely, SOD [Cu-Zn] 
is a free radical scavenger which converts superoxide to hydrogen peroxide and 
has been shown to be renoprotective.169, 180  Elevated concentrations of SOD 




have previously found that angiotensin predicts adverse outcomes in patients 
with established AKI, but had not directly compared it to more well-characterized 
AKI biomarkers.  In this analysis, we found that angiotensinogen compared 
favorably with L-FABP.  These data solidify our previous findings and emonstrate 









Mechanistic Insights and Unanswered Questions: The Renin-Angiotensin 
System and AKI  
Not only do biomarkers provide information useful for guiding clinical care, but 
they can also yield mechanistic insights into the molecular underpinnings of the 
associated disease.  The studies that have been presented have convincingly 
shown that elevated concentrations of urinary angiotensinogen and renin are 
associated with more severe AKI and adverse outcomes.  These two proteins are 
the substrate and enzyme, respectively, of the rate limiting step of the renin 
angiotensin system (RAS).169  It has long been recognized that the RAS plays a 
central role in chronic kidney disease (CKD), and RAS inhibitors are the standard 
of care for patients afflicted with CKD.181, 182  An increase in angiotensinogen is 
prerequisite for activation of the RAS and generation of downstream effector 
angiotensin peptides, and it is believed that urinary angiotensinogen is a 
surrogate for intrarenal activation of the renin-angiotensin system (RAS) during 
chronic kidney disease.148, 183-185  Importantly, Kim et al. have shown that urinary 
angiotensinogen concentration correlates with urinary TGF-β, a profibrotic 
cytokine, and with the degree of the severity of the renal histopathology of 
patients with CKD.186  Given its biological relationship with angiotensinogen, it is 
logical that urinary renin excretion could also be an important index of intrarenal 
RAS activation in chronic kidney disease. 





in the collecting duct via AT1R signaling, which results in tubular secretion of 
prorenin and renin.187  In light of what is known about RAS and the importance of 
urinary angiotensinogen and renin in CKD, our findings require us to consider the 
possibility that the RAS could modulate the severity of renal injury during an 
episode of AKI.  Certainly this would be congruent with the data from animal 
models of AKI (see below).  Furthermore, as mentioned in the introduction in 
Chapter 1, AKI can precipitate CKD and accelerate its progression.  Could the 
RAS be the mechanism which underlies this epidemiologic association?  It is 
certainly plausible.  If indeed this is the case, then it is likely that monitoring 
urinary angiotensinogen and renin levels during the course of AKI could predict 
which patients will develop CKD or progress from CKD to end stage renal 
disease (ESRD).   
Animal models of AKI have repeatedly demonstrated that RAS activation occurs 
during AKI, and that it exerts a negative effect on the severity of the injury.  Allred 
et al. showed that angiotensin II increases in kidney tissue following ischemia 
reperfusion injury in rats, whereas angiotensin I and angiotensin 1-7 increase in 
the urine.188 These findings are supported by a study by da Silveira et al., which 
showed that not only does angiotensin II increase, but angiotensin 1-7, a 
potential counterbalance of angiotensin II effects, decreases in renal tissue 
following ischemia reperfusion injury in a rat model of AKI.189 Greater amounts of 
renal angiotensin II that are observed during AKI could result in increased 
intrarenal inflammation, since models of chronic renal injury have shown that 




mediated by the NF-κB pathway.190-194  Indeed, inhibition of angiotensin 
converting enzyme and the angiotensin II type 1 receptor with captopril and 
losartan, respectively, reduce renal inflammation in rats subjected to renal 
ischemia-reperfusion injury and mitigate the severity of AKI in this model.195, 196  
It is commonly believed that RAS inhibitors can precipitate and exacerbate AKI.  
Some observational studies have noted an increased risk of AKI associated with 
RAS blockade, which is presumably due to the inhibition of angiotensin II 
mediated vasoconstriction of the efferent arteriole.197-199  This results in lower 
hydrostatic pressure in the glomerulus, resulting in a decreased glomerular 
filtration rate (GFR) and an increase in serum creatinine.  Therefore, the effect of 
RAS inhibitors on AKI incidence could be artificial and unrelated to the effect of 
RAS inhibitors on renal injury, and it could be possible that RAS inhibitors 
attenuate renal injury while simultaneously decreasing renal function.  
Unfortunately, the effect of RAS inhibitors of the incidence of severe AKI and its 
complications has not been thoroughly investigated.  Our work would seem to 
suggest that the incidence might be decreased, and therefore an observational 
study on the effect of RAS inhibitor use and AKI severity would be a logical 
extension of the biomarker data that has been presented.  We would hypothesize 
that the effect of RAS inhibitors on GFR could result in an increased rate of 
complications from AKI such as uremic encephalopathy, hyperkalemia, metabolic 
acidosis, and volume overload, but that if these complications are appropriately 
managed, RAS inhibitors could mitigate the mortality rate associated with severe 




recognize that this is in stark contrast to conventional wisdom, it is noteworthy 
that a recent review proposed the continuation of RAS inhibitors during AKI.200                     
Intrarenal or Systemic: The Question of Location 
Classically, the RAS has been understood as a systemic hormonal cascade in 
which angiotensinogen is produced by the liver and renin is released into 
circulation by the juxtaglomerular apparatus in the afferent arterioles of kidney.  
However, the existence of a local RAS in the kidney is widely recognized, and an 
important question that remains unanswered by our work is whether this or the 
systemic RAS is the source of increased angiotensinogen and renin that we have 
observed in the urine of patients with more severe AKI.147,201  We believe that the 
tubular compartment is the likely source of these urine proteins during AKI.  Early 
work by Ingelfinger et al. demonstrated localization of angiotensinogen 
messenger RNA in rat proximal tubules, a finding that was subsequently verified 
in human tissue.202, 203 This indicates that the proximal tubule itself is capable of 
angiotensinogen biosynthesis.  In support of this idea, a recent multiphoton 
imaging study reported negligible glomerular filtration of plasma angiotensinogen 
and concluded that urinary angiotensinogen concentration reflects intrarenal 
production.204  On the contrary, elegant studies using tissue specific and 
conditional knockout mice have demonstrated that under normal conditions 
tubular angiotensinogen protein is primarily derived from the liver and depends 
on megalin for its uptake.205, 206  Thus, it is possible that the urinary 
angiotensinogen detected in our assays was synthesized in the liver and 




injury.  However, a limitation of the knockout animal studies is that they have 
investigated intrarenal angiotensinogen in the uninjured state, and so their 
findings may not reflect what occurs during AKI.  Therefore, AKI induced 
angiotensinogen biosynthesis by the proximal tubule cannot be ruled out, since 
this is a well-established phenomenon.202, 207  Similarly, renin is classically 
understood as secreted by the juxtaglomerular apparatus into circulation.  Renin 
protein can be localized in the proximal tubule, and like angiotensinogen, 
appears to be dependent on megalin uptake.206  However, renin is expressed 
along renal tubular epithelium, and in vivo microscopy has shown that renin 
production increases in the collecting duct during diabetic nephropathy.208  A 
similar mechanism could underlie the increased concentration of urinary renin 
that we observed in patients with more severe AKI.   
Despite the evidence for intrarenal production of angiotensinogen and renin 
during chronic renal injury, which could be paralleled during acute injury, we must 
acknowledge that such deductive reasoning is inconclusive.  A potential future 
direction of this project is to determine the site of angiotensinogen and renin 
production during AKI using animal models of AKI (such as renal 
ischemia/reperfusion injury).  Increased intrarenal expression of these genes and 
protein abundance after renal injury suggest the kidney as the source of these 
urine proteins.  However, kidney-specific knockouts of angiotensinogen and renin 
would be needed to definitively prove intrarenal production.         
Implications for Clinical Trials of AKI 




trials, there are no effective interventions for AKI, and treatment is supportive in 
nature.  There are at least three reasons for this translational bottleneck: 1) late 
initiation of therapy during the trial 2) the complex and multifactorial nature of AKI 
pathobiology and 3) underpowered study design.  Novel biomarkers of AKI can 
address each of these issues.  Serum creatinine, the conventional AKI 
biomarker, is a surrogate of the glomerular filtration rate, and as described in 
chapter 1, it increases as GFR declines during the early phases of AKI.  
However, it increases slowly and elevated sCr is often not detected until 1-3 days 
after the renal injury has occurred.  Therefore, clinical trials which rely upon 
increased serum creatinine for AKI diagnosis and enrollment are unlikely to find a 
positive effect on acute outcomes.  Recognition of this limitation of creatinine has 
been the primary driving force behind AKI biomarker research, leading to the 
discovery of several “early” AKI biomarkers.  Secondly, biomarkers can function 
as molecular phenotyping tools that distinguish between different subtypes of 
disease, perhaps identifying a subpopulation in which intervention is effective.  
While no AKI biomarkers have been proposed for this purpose, examples of 
biomarker driven clinical care abound in the oncology literature, and our findings 
regarding angiotensinogen and renin are particularly attractive for this purpose.  
Given the discussion above, it seems likely that the RAS is involved 
mechanistically in AKI, and it could be that RAS blockade could have a benefit in 
patients with elevated urine concentrations of these proteins.  Finally, the 
inclusion of patients with mild AKI in clinical trials, while commensurate with the 




severe adverse outcomes and diminishing the effect size of an intervention.  
Thus very large sample sizes are needed to demonstrate efficacy.  Prognostic 
biomarkers such as angiotensinogen and renin, which predict progression to 
more severe AKI and a higher risk of adverse outcomes, could therefore be used 
to screen for inclusion in a trial.      
Despite the strong rationale for incorporating biomarkers in AKI trial design, only 
one trial, the EARLYARF Trial, has used biomarker screening as a guide to 
enrollment.142  In this trial, urinary alkaline phosphatase (AP) and gamma-
glutamyl transferase (GGT) values were monitored in ICU and post cardiac 
surgery patients and were used to screen patients for enrollment in a 
randomized, prospective, placebo-controlled clinical trial investigating the effect 
of erythropoietin on AKI incidence.  Unfortunately, this trial failed to demonstrate 
an effect.  However, it serves as an illustrative example.  The underlying reason 
for the failure of erythropoietin is not likely to be late initiation of therapy, since 
increased urine concentrations of these brush border enzymes is thought to be 
an early marker of renal injury.  Rather, there are two more plausible 
explanations.  First, the putative renoprotective mechanism of erythropoietin is 
attenuation of ischemia-reperfusion injury.209, 210  While GGT and AP do increase 
following ischemic tubular injury, they are not specific for ischemic injury.  The 
heterogeneity of the study cohort itself is evidence of this, as there were a 
significant number of the patients who had septic AKI and AKI after cardiac 
surgery, both of which have complex, multifactorial pathogenesis.211, 212  This 




erythropoietin administration.  Secondly, the investigators ran an observational 
study in parallel with the trial to determine the effectiveness of biomarker 
screening at enriching the study population.  It seems that GGT and AP guided 
enrollment only marginally enriched the study population, resulting in only a small 
increase in statistical power of the study.  For example, biomarker guided 
enrollment increased the incidence of AKI from 15.1% to 23.0% and 7 day 
mortality from 8.1% to 14.2% (P = 0.034).  While the .investigators explicitly 
stated in the manuscript that AP and GGT were the only confirmed AKI 
biomarkers available for rapid detection at the time the study was conducted, it 
begs the question of how the trial would have concluded if a more accurate 
biomarker had been used.   
The design of the EARLY ARF trial raises an important question for AKI 
biomarker research.  Namely, how good does a biomarker need to be in order to 
be useful in clinical trial design?  A recent NIDDK workshop on AKI clinical trial 
design stated,  
“Although numerous novel biomarkers have been proposed for 
early identification of intrinsic AKI, to date no biomarker has been 
shown to possess sufficient predictive ability to be used as a 
primary enrollment criterion and should not supplant SCr [serum 
creatinine] for enrollment into trials exploring the effects of agents 
on established AKI.”213   




stratification in AKI trials should continue to be investigated.  Specific 
recommendations for assessing this potential were not prescribed, and it remains 
largely unclear how to define the advantages gained by using a biomarker as a 
guide for enrollment.  It is obvious, however, that the advantages and 
disadvantages of biomarker guided clinical trial enrollment are best understood in 
terms of the benefit of enrichment and the cost of screening.  It is our objective to 
provide a logical framework for performing a cost-benefit analysis to determine if 
biomarker guided enrollment might be beneficial for future AKI clinical trials.     
Enrichment: The Benefit of Biomarker Guided Enrollment 
Enrichment strategies are commonplace in clinical trial design.141  Their purpose 
is to increase the proportion of patients in the study population who might benefit 
from an experimental intervention, with the results being increased effect size 
(i.e. absolute risk reduction), increased statistical power, and a decrease in the 
sample size needed to achieve a given power.  To describe the advantages of 
enrichment, let us consider the fenoldopam trial conducted by Tumlin et al.214  
This prospective, randomized, double-blind, placebo controlled clinical trial (n = 
155) found that fenoldopam, a dopamine receptor alpha-1 specific agonist, failed 
to reduce the rate of renal replacement therapy or death within 21 days (p = 
0.163).  The incidence of this outcome in the placebo group (n = 75) was 38.7%, 
whereas in the treatment arm (n = 80) 27.5% of the patients met the outcome 
(relative risk reduction of 28.9%).  The power to detect an effect size of 11.2% 
with this sample size is 0.331.  In order to achieve a power of 0.8, the 




how biomarker guided enrollment might have altered the outcome of this trial, 
consider the combination of urinary angiotensinogen and renin that was 
described in Chapter 5.  This biomarker test identified patients at high risk of 
progressing from AKIN stage 1 to the composite endpoint AKIN stage 3 or death 
(sensitivity = 30.4%; specificity = 98.9%).  This outcome is quite comparable to 
the composite outcome renal replacement therapy or death chosen by Tumlin et 
al.  Assuming the same sensitivity and specificity, this test would have a PPV of 
94.6% in the population used in the fenoldopam trial.  If the 
angiotensinogen/renin combination had been used to enrich the study population 
of the fenoldopam trial, the power would have been 0.996, assuming no change 
in sample size or the relative risk reduction conferred by fenoldopam treatment.  
The increase in power is due to an increase in the absolute difference in the 
proportions of subjects meeting the endpoint between the experimental groups 
from 11.2% (38.7% -27.5%) to 27.4% (94.6% - 67.2%). Importantly, however, 
because of the increased power, one of the most significant benefits of 
enrichment is that, compared to the unenriched population, fewer patients will 
need to be enrolled in the trial to detect a difference between the treatment 
group, and we calculate that the number needed to enroll trial to attain a power of 
0.8 (NNEPower 0.8) in an angiotensinogen/renin enriched fenoldopam AKI clinical is 
only 62 patients.      
Mathematically, enrichment is simply defined as the ratio of PPV to prevalence.  
The benefit of enrichment can be appreciated by examining the changes in the 




illustrated in Table 7.1.  The number needed to enroll (NNE) is the number of 
patients that need to be enrolled in order to enroll one patient who will meet the 
outcome (one event).  In an unenriched trial, NNE is simply the reciprocal of the 
prevalence of the outcome (Equation 7.1a); in a biomarker enriched trial, NNE is 
the reciprocal of the PPV of the biomarker test (Equation 7.1b).  If the desired 
number of events is known, then the total enrollment that will be necessary is 
given by the product of NNE and the target number of events.  Equivalently, 
because enrichment increases the absolute risk reduction (ARR) of an 
intervention, it results in a decrease in the number needed to treat (NNT), which 
is the reciprocal of the ARR.  Importantly, the PPV/prevalence ratio is equal to 
the unenriched-to-enriched NNE and NNT ratios.  Therefore we propose that 
when evaluating the potential use of a biomarker in clinical trial design that this 
“enrichment index” be calculated (Equation 7.2), because of the ease of 
interpreting this number as a measure of the degree of enrichment and its effect 
on the observed treatment response rate.  Furthermore, the statistical 
significance of the enrichment index can be readily determined using the χ2 test.  
However, since this test relies both on proportions and frequencies, we propose 
that by convention, the proportion of 100 patients who meet the outcome be 
calculated using the prevalence and compared to the number (out of 100) 
calculated using the PPV (Figure 7.1).  While this is a somewhat crude approach, 







Equation 7.1a  NNEu = 1/Prevalence 
Equation 7.1b NNEE = 1/PPV 
Equation 7.2  EI = PPV/Prevalence = NNEu/NNEE = NNTU/NNTE 
The subscripts U and E indicate unenriched and enriched populations, 
respectively.  EI, enrichment index; PPV, positive predictive value of the 




worth the cost of screening.  Using this approach, it appears that the enrichment 
index of angiotensinogen/renin is statistically significant (P< 0.001). 
Screening: The Cost of Biomarker Guided Enrollment 
The second aspect that must be considered when evaluating the potential of a 
biomarker for guided enrollment is the cost of screening.  This can be estimated 
by calculating the number of patients who will need to be screened in order to 
enroll one patient (number needed to screen; NNS).  Because only patients with 
a positive test result will be enrolled, the NNS is mathematically determined by 
the proportion of patients who test positive (i.e. the sum of the true positive and 
false positive rates).  The NNS is equal to the reciprocal of the positive rate of the 
test (Equation 7.3a).  Assuming prevalence = 38.7%; sensitivity = 30.4%; and 
specificity = 98.9%, the NNS of the angiotensinogen/renin CHAID model would 
be 8.  Therefore, in order to match the enrollment of the fenoldopam trial, 1240 
patients need to be screened. From this analysis, the NNS seems to 
unreasonably large, and we might erroneously reject the use of the 
angiotensinogen/renin combination to guide enrollment.  However, the NNS does 
not tell us how many patients will need to be screened to conduct the trial; it is 
merely an estimate of the rate of screening to enrollment.  Furthermore, we have 
already demonstrated that due to benefits of enrichment, a biomarker guided trial 
will need to enroll fewer patients than an unenriched trial to reach a given 
statistical power.  In order to calculate how many patients will be needed conduct 
the trial if a biomarker were used to enrich the study population, power and 










   
               
 
Equation 7.3a NNS = 1/[(P*Sensitivity) +[(1-P)(1-Specificity)]] 
Equation 7.3b    NNSPower 0.8 = NNS * SSPower 0.8 
Where P = prevalence; NNS = number of patients that need to be screened to enroll 
one patient; SSPower 0.8 = the number of patients that would need to be enrolled to 
attain Power of 0.8; NNSPower 0.8 = number patients that will need to be screened to 




been determined, then the NNS can be used to calculate the number of patients 
that will need to be screened to meet that target enrollment (NNSPower 0.8; 
Formula 7.3b).  Therefore, if we use the sample size calculation performed above 
for a power of 0.8, then we estimate that 491 patients would need to be screened 
to meet the target enrollment of 62.  Thus the number screened is actually less 
than the number of patients who would need to be enrolled to achieve a power of 
0.8 if all comers were enrolled (n = 553), indicating that the cost of screening is 
less than the benefit of enrichment.  A schematic for evaluating the costs and 
benefits of biomarker guided enrollment is shown in Figure 7.2.   
Discussion of Cost-Benefit Analysis 
It must be noted that the framework which we have provided has some obvious 
limitations.  The suggested calculations are performed a priori and consequently 
are heavily dependent upon assumptions of prevalence, biomarker test 
performance characteristics, and the relative risk reduction of the intervention.  
Accordingly, prevalence of the primary outcome of a clinical trial should be 
estimated from historical data in the study population to maximize the accuracy 
of the estimate.  Similarly, biomarker test performance should be well 
characterized in a prospective observational study in the same population that 
will be used in the clinical trial.  This was the major pitfall of the EARLYARF trial, 
because the investigators used a cut-off that had been determined from an 
extremely small (n = 26) prospective study in which only 4 subjects developed 





Figure 7-2. Schematic for evaluating the benefit and cost of incorporating biomarker 
guided enrollment into clinical trial design. The first step is to estimate the prevalence of 
the primary outcome (P) and the relative risk reduction (RRR) conferred by the intervention.  
Prevalence should then be used to calculate the positive predictive value (PPV) of the 
biomarker test.  The enrichment index (EI) should be calculated and statistical significance 
determined using the χ2 test as described in the text.  Power and sample size analysis should 
be performed for the unenriched (white box) and enriched trials (light gray boxes) using the P 
and PPV, respectively, for the event rates in the placebo arm, keeping RRR constant.  The 
sample size (SS) calculated for a give power (Power X) should be determined for both studies, 
and the NNS should be used to calculate the total number of patients that would need to be 
screened to enroll that number of patients in the biomarker enriched trial (NNSPower X).  This 
should then be compared to the SS calculated for the unenriched trial at that power          




angiotensinogen and renin were evaluated in a retrospective cohort study in a 
population that differed from that of the fenoldopam trial.  Finally, the relative risk 
reduction conferred by an intervention in a biomarker enriched trial has been 
assumed to be identical to that of an unenriched trial.  Unfortunately, this may not 
be true.  Because biomarkers subclassify a disease according to molecular 
phenotype, the study populations of a biomarker enriched and unenriched trials 
are not identical, and thus the effect size of an intervention is unlikely to be the 
same.  Unfortunately it is not possible to determine what the difference in the 
performance of an intervention might be in the enriched population.  There is 
even the possibility that biomarker guided enrichment could abrogate the 
therapeutic effect of an otherwise efficacious intervention, which would lead us to 
falsely conclude that it is not effective.  For this reason, it would be advisable to 
adopt the 2 stage clinical trial strategy proposed by Jones and Holmgren.216-218  
In the first stage, 2 pilot trials are conducted in which the intervention is tested in 
biomarker enriched population and an unenriched population.  The second stage 
is a larger, phase II trial conducted using the population in which the intervention 
demonstrated efficacy in stage 1.  If there is no difference in the efficacy between 
the enriched and unenriched groups, then the biomarker enriched population 
could be used to reduce the enrollment in the second stage, potentially 
accelerating the conclusion of the trial and decreasing the time needed to bring 
an intervention to the general population.  An additional advantage of the 2 stage 
approach is that it allows us to determine if the intervention is only efficacious in 




biomarker were an index of the mechanism which is targeted by an intervention, 
and in fact, the oncology literature is replete with examples of biomarker driven 
therapy.  In addition to benefitting biomarker positive patients, correlating efficacy 
with biomarker status is an important finding from an ethical perspective because 
it would prevent the treatment of biomarker negative patients with an intervention 
from which they will not benefit.  Therefore, we hypothesize that patients with 
elevated urinary angiotensinogen and renin could represent a subpopulation in 
which inhibitors of the renin-angiotensin system could attenuate the severity of 
AKI, whereas other patients without elevated urinary angiotensinogen and renin 
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